text_a,span_text_a,text_b,span_text_b,normalized_vertical_gap,indentation_change,same_alignment,is_centered_A,is_centered_B,font_size_a,font_size_b,font_size_diff,same_font,is_bold_A,is_bold_B,is_italic_A,is_italic_B,is_monospace_A,is_monospace_B,same_bold,same_italic,same_monospace,line_a_ends_punctuation,line_b_starts_lowercase,is_linea_in_rectangle,is_lineb_in_rectangle,both_in_table,neither_in_table,is_linea_hashed,is_lineb_hashed,both_hashed,neither_hashed,page_number_a,page_number_b,label
"unlike GraphDRP and XGDP, tCNN used 1D convolutional layers to encode the SMILES notation of drugs,","unlike GraphDRP and XGDP, tCNN used 1D convolutional layers to encode the SMILES notation of drugs,",which renders it infeasible to decode the developed models to investigate structural saliency of drugs upon,which renders it infeasible to decode the developed models to investigate structural saliency of drugs upon,-0.28,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
which renders it infeasible to decode the developed models to investigate structural saliency of drugs upon,which renders it infeasible to decode the developed models to investigate structural saliency of drugs upon,reaction with cancer cells.,reaction with cancer cells.,-0.28,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
reaction with cancer cells.,reaction with cancer cells.,Blind prediction of responses of unknown drugs,Blind prediction of responses of unknown drugs,0.93,0,1,0,1,9,10,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0
Blind prediction of responses of unknown drugs,Blind prediction of responses of unknown drugs,"In the blind test of response prediction of unknown drugs, we divide the dataset by constraining the existence of","In the blind test of response prediction of unknown drugs, we divide the dataset by constraining the existence of",-0.17,0,1,1,0,10,9,-1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,0
"In the blind test of response prediction of unknown drugs, we divide the dataset by constraining the existence of","In the blind test of response prediction of unknown drugs, we divide the dataset by constraining the existence of","drugs exclusively in training, validation, or testing set. Specifically, out of 223 drugs in total, 167 drugs’ response","drugs exclusively in training, validation, or testing set. Specifically, out of 223 drugs in total, 167 drugs’ response",-0.28,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
"drugs exclusively in training, validation, or testing set. Specifically, out of 223 drugs in total, 167 drugs’ response","drugs exclusively in training, validation, or testing set. Specifically, out of 223 drugs in total, 167 drugs’ response","data are used for a 3-fold cross-validation, and response data of 56 drugs are preserved for testing. The blind","data are used for a 3-fold cross-validation, and response data of 56 drugs are preserved for testing. The blind",-0.28,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
"data are used for a 3-fold cross-validation, and response data of 56 drugs are preserved for testing. The blind","data are used for a 3-fold cross-validation, and response data of 56 drugs are preserved for testing. The blind",prediction task aims at testing whether the model developed on known drugs has the generalizability to predict,prediction task aims at testing whether the model developed on known drugs has the generalizability to predict,-0.28,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
prediction task aims at testing whether the model developed on known drugs has the generalizability to predict,prediction task aims at testing whether the model developed on known drugs has the generalizability to predict,responses of unknown drugs.,responses of unknown drugs.,-0.28,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
responses of unknown drugs.,responses of unknown drugs.,"In the blind test experiment, we compare our method with tCNN, GraphDRP and TGSA. DeepCDR is ignored","In the blind test experiment, we compare our method with tCNN, GraphDRP and TGSA. DeepCDR is ignored",-0.28,12,0,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0
"In the blind test experiment, we compare our method with tCNN, GraphDRP and TGSA. DeepCDR is ignored","In the blind test experiment, we compare our method with tCNN, GraphDRP and TGSA. DeepCDR is ignored",since the code to flexibly divide the dataset according to drug occurrence is not provided. As shown in Table,since the code to flexibly divide the dataset according to drug occurrence is not provided. As shown in Table,-0.28,-12,0,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
since the code to flexibly divide the dataset according to drug occurrence is not provided. As shown in Table,since the code to flexibly divide the dataset according to drug occurrence is not provided. As shown in Table,"2, GAT- and GATE-based XGDP remarkably outperform other models. All baseline methods fail to perform","2, GAT- and GAT_E-based XGDP remarkably outperform other models. All baseline methods fail to perform",-0.28,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1
"2, GAT- and GATE-based XGDP remarkably outperform other models. All baseline methods fail to perform","2, GAT- and GAT_E-based XGDP remarkably outperform other models. All baseline methods fail to perform","well on blind test, especially in terms of R 2, which is in accordance with their original research 11,25,27 . tCNN and","well on blind test, especially in terms of R2, which is in accordance with their original research11,25,27. tCNN and",-0.28,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
"well on blind test, especially in terms of R 2, which is in accordance with their original research 11,25,27 . tCNN and","well on blind test, especially in terms of R2, which is in accordance with their original research11,25,27. tCNN and","TGSA achieves a very small R 2 value ~0.02 and GraphDRP even results in negative R 2 values, which indicates","TGSA achieves a very small R2 value (~0.02) and GraphDRP even results in negative R2 values, which indicates",-0.28,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1
"TGSA achieves a very small R 2 value ~0.02 and GraphDRP even results in negative R 2 values, which indicates","TGSA achieves a very small R2 value (~0.02) and GraphDRP even results in negative R2 values, which indicates","these models are not making a sensible prediction when a brand new drug is given. Nevertheless, GAT-based","these models are not making a sensible prediction when a brand new drug is given. Nevertheless, GAT-based",-0.28,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
"these models are not making a sensible prediction when a brand new drug is given. Nevertheless, GAT-based","these models are not making a sensible prediction when a brand new drug is given. Nevertheless, GAT-based",XGDP models with and without edge features are able to achieve a significant improvement compared with the,XGDP models with and without edge features are able to achieve a significant improvement compared with the,-0.28,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1
XGDP models with and without edge features are able to achieve a significant improvement compared with the,XGDP models with and without edge features are able to achieve a significant improvement compared with the,baselines.,baselines.,-0.28,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
baselines.,baselines.,"XGDP achieves state-of-the-art performance in both rediscovery and blind test. However, scrutinizing the","XGDP achieves state-of-the-art performance in both rediscovery and blind test. However, scrutinizing the",-0.28,12,0,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0
"XGDP achieves state-of-the-art performance in both rediscovery and blind test. However, scrutinizing the","XGDP achieves state-of-the-art performance in both rediscovery and blind test. However, scrutinizing the","results of XGDP with various GNN types, it is observed that incorporating chemical bond type as edge features","results of XGDP with various GNN types, it is observed that incorporating chemical bond type as edge features",-0.28,-12,0,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
"results of XGDP with various GNN types, it is observed that incorporating chemical bond type as edge features","results of XGDP with various GNN types, it is observed that incorporating chemical bond type as edge features",or relation types in relational GNNs does not always give rise to a better performance. Despite that RGCN,or relation types in relational GNNs does not always give rise to a better performance. Despite that RGCN,-0.28,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
or relation types in relational GNNs does not always give rise to a better performance. Despite that RGCN,or relation types in relational GNNs does not always give rise to a better performance. Despite that RGCN,"outperforms GCN in both tasks, GAT-based XGDP suppresses all other edge-enhanced GAT models in Table","outperforms GCN in both tasks, GAT-based XGDP suppresses all other edge-enhanced GAT models in Table",-0.28,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
"outperforms GCN in both tasks, GAT-based XGDP suppresses all other edge-enhanced GAT models in Table","outperforms GCN in both tasks, GAT-based XGDP suppresses all other edge-enhanced GAT models in Table","1, and in Table 2, only GATE performs better than plain GAT convolution. Nonetheless, in the next section,","1, and in Table 2, only GAT_E performs better than plain GAT convolution. Nonetheless, in the next section,",-0.28,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1
"1, and in Table 2, only GATE performs better than plain GAT convolution. Nonetheless, in the next section,","1, and in Table 2, only GAT_E performs better than plain GAT convolution. Nonetheless, in the next section,","we will demonstrate that, to investigate the structural importance of molecules, it is essential to include edge","we will demonstrate that, to investigate the structural importance of molecules, it is essential to include edge",-0.28,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
"we will demonstrate that, to investigate the structural importance of molecules, it is essential to include edge","we will demonstrate that, to investigate the structural importance of molecules, it is essential to include edge",features as well.,features as well.,-0.28,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
features as well.,features as well.,Prediction without cross-attention layers,Prediction without cross-attention layers,0.93,0,1,0,0,9,10,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0
Prediction without cross-attention layers,Prediction without cross-attention layers,"To investigate the role of the cross-attention layers, we conducted an ablation study to compare XGDP with or","To investigate the role of the cross-attention layers, we conducted an ablation study to compare XGDP with or",-0.17,0,1,0,0,10,9,-1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,0
"To investigate the role of the cross-attention layers, we conducted an ablation study to compare XGDP with or","To investigate the role of the cross-attention layers, we conducted an ablation study to compare XGDP with or","without the attention layers. Particularly, we removed the two cross-attention modules following the GNN and","without the attention layers. Particularly, we removed the two cross-attention modules following the GNN and",-0.28,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
"without the attention layers. Particularly, we removed the two cross-attention modules following the GNN and","without the attention layers. Particularly, we removed the two cross-attention modules following the GNN and","CNN, and directly concatenated the features learned by the GNN and CNN modules as the input of the final","CNN, and directly concatenated the features learned by the GNN and CNN modules as the input of the final",-0.28,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1
"CNN, and directly concatenated the features learned by the GNN and CNN modules as the input of the final","CNN, and directly concatenated the features learned by the GNN and CNN modules as the input of the final","dense layer. As shown in Table 3, it is evident that the cross-attention layer enhances the performance of drug","dense layer. As shown in Table 3, it is evident that the cross-attention layer enhances the performance of drug",-0.28,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
"dense layer. As shown in Table 3, it is evident that the cross-attention layer enhances the performance of drug","dense layer. As shown in Table 3, it is evident that the cross-attention layer enhances the performance of drug",response prediction and maintains better stability.,response prediction and maintains better stability.,-0.28,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
response prediction and maintains better stability.,response prediction and maintains better stability.,Discovery of drug mechanisms,Discovery of drug mechanisms,1.07,0,1,0,0,9,11,2,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0
Discovery of drug mechanisms,Discovery of drug mechanisms,"We decode our models with GNNExplainer and Integrated Gradients, and present the attribution results of","We decode our models with GNNExplainer and Integrated Gradients, and present the attribution results of",-0.2,0,1,0,0,11,9,-2,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,0
"We decode our models with GNNExplainer and Integrated Gradients, and present the attribution results of","We decode our models with GNNExplainer and Integrated Gradients, and present the attribution results of",our best performing GATv2 model in this section. GNNExplainer is leveraged to explain the model’s graph,our best performing GATv2 model in this section. GNNExplainer is leveraged to explain the model’s graph,-0.28,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
our best performing GATv2 model in this section. GNNExplainer is leveraged to explain the model’s graph,our best performing GATv2 model in this section. GNNExplainer is leveraged to explain the model’s graph,"convolutional layers, and thus attribute the input molecular graphs. By interpreting a reaction pair of drug","convolutional layers, and thus attribute the input molecular graphs. By interpreting a reaction pair of drug",-0.28,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
"convolutional layers, and thus attribute the input molecular graphs. By interpreting a reaction pair of drug","convolutional layers, and thus attribute the input molecular graphs. By interpreting a reaction pair of drug","and cell line, each node and edge in the molecular graph is assigned with a saliency score. For each drug, we","and cell line, each node and edge in the molecular graph is assigned with a saliency score. For each drug, we",-0.28,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
"and cell line, each node and edge in the molecular graph is assigned with a saliency score. For each drug, we","and cell line, each node and edge in the molecular graph is assigned with a saliency score. For each drug, we","sum and average the saliency scores across all the cell lines for each node and edge, and perform a max-min","sum and average the saliency scores across all the cell lines for each node and edge, and perform a max-min",-0.28,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
"sum and average the saliency scores across all the cell lines for each node and edge, and perform a max-min","sum and average the saliency scores across all the cell lines for each node and edge, and perform a max-min",normalization across the nodes or edges in one molecular graph. The normalized scores range from 0 to 1 and,normalization across the nodes or edges in one molecular graph. The normalized scores range from 0 to 1 and,-0.28,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
normalization across the nodes or edges in one molecular graph. The normalized scores range from 0 to 1 and,normalization across the nodes or edges in one molecular graph. The normalized scores range from 0 to 1 and,clearly illustrate the importance of a region of substructures to a drug’s biochemical reaction. The normalized,clearly illustrate the importance of a region of substructures to a drug’s biochemical reaction. The normalized,-0.28,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
clearly illustrate the importance of a region of substructures to a drug’s biochemical reaction. The normalized,clearly illustrate the importance of a region of substructures to a drug’s biochemical reaction. The normalized,"score is thereby used for a heatmap visualization, where red in Figs. 2, 3, 4, and 5 represents high saliency and","score is thereby used for a heatmap visualization, where red in Figs. 2, 3, 4, and 5 represents high saliency and",-0.28,0,1,0,1,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
"score is thereby used for a heatmap visualization, where red in Figs. 2, 3, 4, and 5 represents high saliency and","score is thereby used for a heatmap visualization, where red in Figs. 2, 3, 4, and 5 represents high saliency and",blue represents low saliency.,blue represents low saliency.,-0.28,0,1,1,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
blue represents low saliency.,blue represents low saliency.,"To investigate the gene saliency in the pharmacodynamic process, we aggregate the saliency scores across all","To investigate the gene saliency in the pharmacodynamic process, we aggregate the saliency scores across all",-0.28,12,0,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0
"To investigate the gene saliency in the pharmacodynamic process, we aggregate the saliency scores across all","To investigate the gene saliency in the pharmacodynamic process, we aggregate the saliency scores across all","the cell lines for each drug in the test set, and thereby rank and select the top 50 genes with highest accumulated","the cell lines for each drug in the test set, and thereby rank and select the top 50 genes with highest accumulated",-0.28,-12,0,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
"the cell lines for each drug in the test set, and thereby rank and select the top 50 genes with highest accumulated","the cell lines for each drug in the test set, and thereby rank and select the top 50 genes with highest accumulated",scores. Attribution of four drugs are illustrated as examples to support this study in the following sections.,scores. Attribution of four drugs are illustrated as examples to support this study in the following sections.,-0.28,0,1,0,1,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
scores. Attribution of four drugs are illustrated as examples to support this study in the following sections.,scores. Attribution of four drugs are illustrated as examples to support this study in the following sections.,Method Conv type RMSE  ?  PCC  ?  R 2  ?,Conv type,7.55,50.75,0,1,0,9,7,-2,0,0,1,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,1,1,1,0
Method Conv type RMSE  ?  PCC  ?  R 2  ?,Conv type,GCN 0.063 ± 0.002 0.450 ± 0.026 0.153 ± 0.048,0.063 ± 0.002,1.86,41.87,0,0,1,7,7,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,1,1,1,1
GCN 0.063 ± 0.002 0.450 ± 0.026 0.153 ± 0.048,0.063 ± 0.002,GraphDRP 25,GraphDRP25,-0.45,-89.48,0,1,0,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,1,1,1
GraphDRP 25,GraphDRP25,GAT 0.071 ± 0.003 0.351 ± 0.165 -0.041 ± 0.045,0.041 ± 0.045,-0.43,182.71,0,0,0,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,1,1,1
GAT 0.071 ± 0.003 0.351 ± 0.165 -0.041 ± 0.045,0.041 ± 0.045,GCN 0.056 ± 0.000 0.400 ± 0.016 0.048 ± 0.015,0.056 ± 0.000,1.87,-93.23,0,0,1,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,1,1,1
GCN 0.056 ± 0.000 0.400 ± 0.016 0.048 ± 0.015,0.056 ± 0.000,GAT 0.053 ± 0.001 0.448 ± 0.036 0.149 ± 0.052,0.053 ± 0.001,0.33,0,1,1,1,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,1,1,1
GAT 0.053 ± 0.001 0.448 ± 0.036 0.149 ± 0.052,0.053 ± 0.001,GATE 0.052 ± 0.003 0.505 ± 0.090 0.164 ± 0.043,0.052 ± 0.003,0.3,0,1,1,1,7,7,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,1,1,1,1
GATE 0.052 ± 0.003 0.505 ± 0.090 0.164 ± 0.043,0.052 ± 0.003,XGDP,XGDP,-0.47,-89.48,0,1,0,7,7,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,1,1,1,1
XGDP,XGDP,GATv2E 0.055 ± 0.002 0.442 ± 0.041 0.058 ± 0.024,0.055 ± 0.002,-0.42,89.48,0,0,1,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,1,1,1
GATv2E 0.055 ± 0.002 0.442 ± 0.041 0.058 ± 0.024,0.055 ± 0.002,RGCN 0.055 ± 0.001 0.405 ± 0.031 0.063 ± 0.045,0.055 ± 0.001,0.33,0,1,1,1,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,1,1,1
RGCN 0.055 ± 0.001 0.405 ± 0.031 0.063 ± 0.045,0.055 ± 0.001,RGAT 0.055 ± 0.002 0.257 ± 0.061 0.063 ± 0.060,0.055 ± 0.002,0.31,0,1,1,1,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,1,1,1
RGAT 0.055 ± 0.002 0.257 ± 0.061 0.063 ± 0.060,0.055 ± 0.002,Table 2 . Performance of proposed and baseline models in task of drug-blind prediction. Best performance,Table 2.  Performance of proposed and baseline models in task of drug-blind prediction. Best performance,1.23,-92.62,0,1,0,7,9,2,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,1,0
Table 2 . Performance of proposed and baseline models in task of drug-blind prediction. Best performance,Table 2.  Performance of proposed and baseline models in task of drug-blind prediction. Best performance,marked in bold is achieved by XGDP-GATE.,(marked in bold) is achieved by XGDP-GAT_E.,-0.15,0,1,0,0,9,9,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1
marked in bold is achieved by XGDP-GATE.,(marked in bold) is achieved by XGDP-GAT_E.,Scientific Reports 2025 15:179 https://doi.org/10.1038/s41598-024-83090-3 8,| https://doi.org/10.1038/s41598-024-83090-3,2.97,69.94,0,0,1,9,8,-1,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0
Method Conv type RMSE  ?  PCC  ?  R 2  ?,Conv type,GCN 0.045 ± 0.018 0.457 ± 0.476 0.480 ± 0.416,0.045 ± 0.018,0.95,36.82,0,0,1,7,7,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,1,2,2,1
GCN 0.045 ± 0.018 0.457 ± 0.476 0.480 ± 0.416,0.045 ± 0.018,GAT 0.038 ± 0.000 0.831 ± 0.003 0.679 ± 0.000,0.038 ± 0.000,1,0,1,1,1,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,2,2,1
GAT 0.038 ± 0.000 0.831 ± 0.003 0.679 ± 0.000,0.038 ± 0.000,XGDP w/o attn,XGDP (w/o attn),-1.38,-92,0,1,0,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,2,2,1
XGDP w/o attn,XGDP (w/o attn),GATE 0.037 ± 0.001 0.834 ± 0.010 0.691 ± 0.020,0.037 ± 0.001,-1.32,92,0,0,1,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,2,2,1
GATE 0.037 ± 0.001 0.834 ± 0.010 0.691 ± 0.020,0.037 ± 0.001,GATv2E 0.035 ± 0.000 0.847 ± 0.001 0.718 ± 0.002,0.035 ± 0.000,1,0,1,1,1,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,2,2,1
GATv2E 0.035 ± 0.000 0.847 ± 0.001 0.718 ± 0.002,0.035 ± 0.000,GCN 0.026 ± 0.000 0.918 ± 0.001 0.843 ± 0.002,0.026 ± 0.000,1,0,1,1,1,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,2,2,1
GCN 0.026 ± 0.000 0.918 ± 0.001 0.843 ± 0.002,0.026 ± 0.000,GAT 0.026 ± 0.000 0.923 ± 0.000 0.851 ± 0.001,0.923 ± 0.000,0.87,45.13,0,1,1,7,7,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,1,2,2,1
GAT 0.026 ± 0.000 0.923 ± 0.000 0.851 ± 0.001,0.923 ± 0.000,XGDP,XGDP,-1.39,-137.13,0,1,0,7,7,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,1,2,2,1
XGDP,XGDP,GATE 0.026 ± 0.000 0.922 ± 0.001 0.849 ± 0.001,0.026 ± 0.000,-5.97,92,0,0,1,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,2,2,1
GATE 0.026 ± 0.000 0.922 ± 0.001 0.849 ± 0.001,0.026 ± 0.000,GATv2E 0.026 ± 0.000 0.921 ± 0.001 0.846 ± 0.001,0.026 ± 0.000,1,0,1,1,1,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,2,2,1
GATv2E 0.026 ± 0.000 0.921 ± 0.001 0.846 ± 0.001,0.026 ± 0.000,Table 3 . Performance of proposed and baseline models in task of drug-blind prediction. Best performance,Table 3.  Performance of proposed and baseline models in task of drug-blind prediction. Best performance,8.39,-95.14,0,1,0,7,9,2,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,2,2,0
Table 3 . Performance of proposed and baseline models in task of drug-blind prediction. Best performance,Table 3.  Performance of proposed and baseline models in task of drug-blind prediction. Best performance,marked in bold is achieved by XGDP-GATE.,(marked in bold) is achieved by XGDP-GAT_E.,-0.45,0,1,0,0,9,9,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,2,2,1
marked in bold is achieved by XGDP-GATE.,(marked in bold) is achieved by XGDP-GAT_E.,Fig. 3 . Comparison of saliency maps generated by XGDP with GAT left column and GATE right column.,Fig. 3.  Comparison of saliency maps generated by XGDP with GAT (left column) and GAT_E (right column).,98.78,0,1,0,0,9,9,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,2,2,0
Fig. 3 . Comparison of saliency maps generated by XGDP with GAT left column and GATE right column.,Fig. 3.  Comparison of saliency maps generated by XGDP with GAT (left column) and GAT_E (right column).,Afatinib first row and OSI-027 second row are used as examples.,Afatinib (first row) and OSI-027 (second row) are used as examples.,-0.84,0,1,0,1,9,9,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,2,2,1
Afatinib first row and OSI-027 second row are used as examples.,Afatinib (first row) and OSI-027 (second row) are used as examples.,"Fig. 4 .  a  Saliency map of Afatinib,  b  binding mode of Afatinib with EGFR.","Fig. 4.  (a) Saliency map of Afatinib, (b) binding mode of Afatinib with EGFR.",77.16,0,1,1,0,9,9,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,2,2,0
"Fig. 4 .  a  Saliency map of Afatinib,  b  binding mode of Afatinib with EGFR.","Fig. 4.  (a) Saliency map of Afatinib, (b) binding mode of Afatinib with EGFR.",Scientific Reports 2025 15:179 https://doi.org/10.1038/s41598-024-83090-3 9,| https://doi.org/10.1038/s41598-024-83090-3,31.83,69.94,0,0,1,9,8,-1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,2,2,0
"Fig. 5 .  a  Saliency map of Imatinib,  b  binding mode of Imatinib with DDR1.","Fig. 5.  (a) Saliency map of Imatinib, (b) binding mode of Imatinib with DDR1.",Necessity of including edge features,Necessity of including edge features,1.58,0,1,0,0,9,10,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,3,3,0
Necessity of including edge features,Necessity of including edge features,"In the section of drug response prediction, we demonstrate that GAT-based XGDP obtained the best performance","In the section of drug response prediction, we demonstrate that GAT-based XGDP obtained the best performance",-0.08,0,1,0,0,10,9,-1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,3,3,0
"In the section of drug response prediction, we demonstrate that GAT-based XGDP obtained the best performance","In the section of drug response prediction, we demonstrate that GAT-based XGDP obtained the best performance","in both rediscovery and blind test. However, we do not observe any benefits of incorporating edge features","in both rediscovery and blind test. However, we do not observe any benefits of incorporating edge features",-0.13,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"in both rediscovery and blind test. However, we do not observe any benefits of incorporating edge features","in both rediscovery and blind test. However, we do not observe any benefits of incorporating edge features","such as bond types into model development. In this section, we will compare the molecular saliency heatmap","such as bond types into model development. In this section, we will compare the molecular saliency heatmap",-0.13,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"such as bond types into model development. In this section, we will compare the molecular saliency heatmap","such as bond types into model development. In this section, we will compare the molecular saliency heatmap",obtained by interpreting GAT-XGDP with and without edge features.,obtained by interpreting GAT-XGDP with and without edge features.,-0.13,0,1,0,1,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
obtained by interpreting GAT-XGDP with and without edge features.,obtained by interpreting GAT-XGDP with and without edge features.,Figure 3 presents the saliency maps generated by interpreting XGDP based on GAT and GATE. We observe,Figure 3 presents the saliency maps generated by interpreting XGDP based on GAT and GAT_E. We observe,-0.13,12,0,1,0,9,9,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,3,3,0
Figure 3 presents the saliency maps generated by interpreting XGDP based on GAT and GATE. We observe,Figure 3 presents the saliency maps generated by interpreting XGDP based on GAT and GAT_E. We observe,"that when edge features are absent in GAT convolutions, the model is likely to assign inconsistent saliency scores","that when edge features are absent in GAT convolutions, the model is likely to assign inconsistent saliency scores",-0.13,-12,0,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"that when edge features are absent in GAT convolutions, the model is likely to assign inconsistent saliency scores","that when edge features are absent in GAT convolutions, the model is likely to assign inconsistent saliency scores","to atoms and bonds that are connected. Specifically, the case of atom with a high positive score and bond with a","to atoms and bonds that are connected. Specifically, the case of atom with a high positive score and bond with a",-0.13,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"to atoms and bonds that are connected. Specifically, the case of atom with a high positive score and bond with a","to atoms and bonds that are connected. Specifically, the case of atom with a high positive score and bond with a",low negative score attached to the atom happens regularly in GAT-based models. This phenomenon thus hinders,low negative score attached to the atom happens regularly in GAT-based models. This phenomenon thus hinders,-0.13,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
low negative score attached to the atom happens regularly in GAT-based models. This phenomenon thus hinders,low negative score attached to the atom happens regularly in GAT-based models. This phenomenon thus hinders,"the study of substructure importance, since attached atom and bond are assigned with highly contrary saliency","the study of substructure importance, since attached atom and bond are assigned with highly contrary saliency",-0.13,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"the study of substructure importance, since attached atom and bond are assigned with highly contrary saliency","the study of substructure importance, since attached atom and bond are assigned with highly contrary saliency","scores. However, this problem is overcomed by GATE-based XGDP which incorporates edge features in model","scores. However, this problem is overcomed by GAT_E-based XGDP which incorporates edge features in model",-0.13,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"scores. However, this problem is overcomed by GATE-based XGDP which incorporates edge features in model","scores. However, this problem is overcomed by GAT_E-based XGDP which incorporates edge features in model","training. In the right column of Fig. 3, the significant red and insignificant blue structures are separated","training. In the right column of Fig. 3, the significant (red) and insignificant (blue) structures are separated",-0.13,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"training. In the right column of Fig. 3, the significant red and insignificant blue structures are separated","training. In the right column of Fig. 3, the significant (red) and insignificant (blue) structures are separated","clearly instead of mixed with each other. Therefore, we conclude that edge features are essential for the model to","clearly instead of mixed with each other. Therefore, we conclude that edge features are essential for the model to",-0.13,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"clearly instead of mixed with each other. Therefore, we conclude that edge features are essential for the model to","clearly instead of mixed with each other. Therefore, we conclude that edge features are essential for the model to",correctly identify salient structures in molecules. The model decoding experiments in the following sections will,correctly identify salient structures in molecules. The model decoding experiments in the following sections will,-0.13,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
correctly identify salient structures in molecules. The model decoding experiments in the following sections will,correctly identify salient structures in molecules. The model decoding experiments in the following sections will,all be conducted on XGDP-GATE model developed in the rediscovery test.,all be conducted on XGDP-GAT_E model developed in the rediscovery test.,-0.13,0,1,0,1,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
all be conducted on XGDP-GATE model developed in the rediscovery test.,all be conducted on XGDP-GAT_E model developed in the rediscovery test.,Chemical structure investigation,Chemical structure investigation,0.43,0,1,1,0,9,10,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,3,3,0
Chemical structure investigation,Chemical structure investigation,"In this section, we took three drugs, i.e., Afatinib, Imatinib and Sunitinib, as examples to illustrate XGDP’s","In this section, we took three drugs, i.e., Afatinib, Imatinib and Sunitinib, as examples to illustrate XGDP’s",-0.08,0,1,0,0,10,9,-1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,3,3,0
"In this section, we took three drugs, i.e., Afatinib, Imatinib and Sunitinib, as examples to illustrate XGDP’s","In this section, we took three drugs, i.e., Afatinib, Imatinib and Sunitinib, as examples to illustrate XGDP’s",capability of capturing salient substructures in drug reactions. We show the saliency heatmap of each drug,capability of capturing salient substructures in drug reactions. We show the saliency heatmap of each drug,-0.13,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
capability of capturing salient substructures in drug reactions. We show the saliency heatmap of each drug,capability of capturing salient substructures in drug reactions. We show the saliency heatmap of each drug,"and its binding mode with the protein target from the Protein Data Bank PDB 54 . For a clearer illustration,","and its binding mode with the protein target from the Protein Data Bank (PDB)54. For a clearer illustration,",-0.13,0,1,0,1,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"and its binding mode with the protein target from the Protein Data Bank PDB 54 . For a clearer illustration,","and its binding mode with the protein target from the Protein Data Bank (PDB)54. For a clearer illustration,",we leveraged the Extended Functional Groups EFG algorithm 55 to identify the common functional groups in,we leveraged the Extended Functional Groups (EFG) algorithm55 to identify the common functional groups in,-0.13,0,1,1,1,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
we leveraged the Extended Functional Groups EFG algorithm 55 to identify the common functional groups in,we leveraged the Extended Functional Groups (EFG) algorithm55 to identify the common functional groups in,"our dataset, and calculated the average of the saliency score of each atom in the functional group to present the","our dataset, and calculated the average of the saliency score of each atom in the functional group to present the",-0.13,0,1,1,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"our dataset, and calculated the average of the saliency score of each atom in the functional group to present the","our dataset, and calculated the average of the saliency score of each atom in the functional group to present the","importance of each functional group in the drug molecules. In the illustrations of drug protein binding mode,","importance of each functional group in the drug molecules. In the illustrations of drug protein binding mode,",-0.13,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"importance of each functional group in the drug molecules. In the illustrations of drug protein binding mode,","importance of each functional group in the drug molecules. In the illustrations of drug protein binding mode,",we show the contacts between drug molecule and its surroundings <5Å.,we show the contacts between drug molecule and its surroundings (<5Å).,-0.13,0,1,0,1,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
we show the contacts between drug molecule and its surroundings <5Å.,we show the contacts between drug molecule and its surroundings (<5Å).,"Afatinib is a famous EGFR inhibitor. According to 56, the acrylamide group in Afatinib is important for its","Afatinib is a famous EGFR inhibitor. According to56, the acrylamide group in Afatinib is important for its",-0.13,12,0,1,1,9,9,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,3,3,0
"Afatinib is a famous EGFR inhibitor. According to 56, the acrylamide group in Afatinib is important for its","Afatinib is a famous EGFR inhibitor. According to56, the acrylamide group in Afatinib is important for its","inhibitation to kinanse activity of the ErbB family of proteins. As shown in Fig. 4, this functional group and","inhibitation to kinanse activity of the ErbB family of proteins. As shown in Fig. 4, this functional group and",-0.13,-12,0,1,1,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"inhibitation to kinanse activity of the ErbB family of proteins. As shown in Fig. 4, this functional group and","inhibitation to kinanse activity of the ErbB family of proteins. As shown in Fig. 4, this functional group and","other binding sites of Afatinib are successfully identified by our model. Imatinib is a DDR1 inhibitor. In Fig. 5,","other binding sites of Afatinib are successfully identified by our model. Imatinib is a DDR1 inhibitor. In Fig. 5,",-0.13,0,1,1,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"other binding sites of Afatinib are successfully identified by our model. Imatinib is a DDR1 inhibitor. In Fig. 5,","other binding sites of Afatinib are successfully identified by our model. Imatinib is a DDR1 inhibitor. In Fig. 5,","important binding sites, corresponding to the crystal structure of the DDR1 kinanse in complex with Imatinib 57,","important binding sites, corresponding to the crystal structure of the DDR1 kinanse in complex with Imatinib57,",-0.13,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"important binding sites, corresponding to the crystal structure of the DDR1 kinanse in complex with Imatinib 57,","important binding sites, corresponding to the crystal structure of the DDR1 kinanse in complex with Imatinib57,","such as the aminopyrimidine group, are assigned with a relatively high saliency score  > 0 . 9 . Sunitinib is a","such as the aminopyrimidine group, are assigned with a relatively high saliency score (> 0.9). Sunitinib is a",-0.13,0,1,0,1,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"such as the aminopyrimidine group, are assigned with a relatively high saliency score  > 0 . 9 . Sunitinib is a","such as the aminopyrimidine group, are assigned with a relatively high saliency score (> 0.9). Sunitinib is a","potent PDGFR inhibitor 58 . In the crystal structure of PDGFR in complex with Sunitinib 6JOK, the bindinghttps://doi.org/10.2210/pdb6JOK/pdb","potent PDGFR inhibitor58. In the crystal structure of PDGFR in complex with Sunitinib (6JOK), the binding",-0.13,0,1,1,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"potent PDGFR inhibitor 58 . In the crystal structure of PDGFR in complex with Sunitinib 6JOK, the bindinghttps://doi.org/10.2210/pdb6JOK/pdb","potent PDGFR inhibitor58. In the crystal structure of PDGFR in complex with Sunitinib (6JOK), the binding",sites have been remarkably identified by our model as shown in Fig.,sites have been remarkably identified by our model as shown in Fig. 6.,-0.13,0,1,0,1,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
sites have been remarkably identified by our model as shown in Fig.,sites have been remarkably identified by our model as shown in Fig. 6.,Biomarker and pathway analysis,Biomarker and pathway analysis,0.43,0,1,1,0,9,10,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,3,3,0
Biomarker and pathway analysis,Biomarker and pathway analysis,Table 4 presents the top genes ranking < 200 in 956 genes identified by XGDP that are recorded to have,Table 4 presents the top genes (ranking < 200 in 956 genes) identified by XGDP that are recorded to have,-0.08,0,1,0,0,10,9,-1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,3,3,0
Table 4 presents the top genes ranking < 200 in 956 genes identified by XGDP that are recorded to have,Table 4 presents the top genes (ranking < 200 in 956 genes) identified by XGDP that are recorded to have,"interactions with the corresponding drugs in the drug-gene interaction database 59 . Particularly, ERBB3 and","interactions with the corresponding drugs in the drug-gene interaction database59. Particularly, ERBB3 and",-0.13,0,1,0,1,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"interactions with the corresponding drugs in the drug-gene interaction database 59 . Particularly, ERBB3 and","interactions with the corresponding drugs in the drug-gene interaction database59. Particularly, ERBB3 and","EGFR are ranked 60 and 78, respectively, out of 956 genes for Afatinib, DDR1 is ranked 16 for Imatinib, and","EGFR are ranked 60 and 78, respectively, out of 956 genes for Afatinib, DDR1 is ranked 16 for Imatinib, and",-0.13,0,1,1,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,3,3,1
"EGFR are ranked 60 and 78, respectively, out of 956 genes for Afatinib, DDR1 is ranked 16 for Imatinib, and","EGFR are ranked 60 and 78, respectively, out of 956 genes for Afatinib, DDR1 is ranked 16 for Imatinib, and","PDGFA is ranked 113 for Sunitinib. Their specific interactions can be viewed in Figs. 3, 4, and 5.","PDGFA is ranked 113 for Sunitinib. Their specific interactions can be viewed in Figs. 3, 4, and 5.",-0.13,0,1,0,1,9,9,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,3,3,1
"PDGFA is ranked 113 for Sunitinib. Their specific interactions can be viewed in Figs. 3, 4, and 5.","PDGFA is ranked 113 for Sunitinib. Their specific interactions can be viewed in Figs. 3, 4, and 5.","Moreover, we perform Gene Set Enrichment Analysis GSEA 60 with GSEApy 61 using the attributed saliency","Moreover, we perform Gene Set Enrichment Analysis (GSEA)60 with GSEApy61 using the attributed saliency",-0.13,12,0,1,1,9,9,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,3,3,0
"Moreover, we perform Gene Set Enrichment Analysis GSEA 60 with GSEApy 61 using the attributed saliency","Moreover, we perform Gene Set Enrichment Analysis (GSEA)60 with GSEApy61 using the attributed saliency",scores. The top 5 enriched terms for each of the example drugs are shown in Table 5 together with their enrichment,scores. The top 5 enriched terms for each of the example drugs are shown in Table 5 together with their enrichment,-0.13,-12,0,1,1,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
scores. The top 5 enriched terms for each of the example drugs are shown in Table 5 together with their enrichment,scores. The top 5 enriched terms for each of the example drugs are shown in Table 5 together with their enrichment,scores ES and normalized enrichment scores NES. The identified pathways are well associated with cancer,scores (ES) and normalized enrichment scores (NES). The identified pathways are well associated with cancer,-0.13,0,1,1,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
scores ES and normalized enrichment scores NES. The identified pathways are well associated with cancer,scores (ES) and normalized enrichment scores (NES). The identified pathways are well associated with cancer,"metastasis and progression. Specifically, epithelial-to-mesenchymal transition EMT, which is one of the top","metastasis and progression. Specifically, epithelial-to-mesenchymal transition (EMT), which is one of the top",-0.13,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"metastasis and progression. Specifically, epithelial-to-mesenchymal transition EMT, which is one of the top","metastasis and progression. Specifically, epithelial-to-mesenchymal transition (EMT), which is one of the top","enriched pathway for all drugs, is responsible for induction of cancer stem cells and immune escape during","enriched pathway for all drugs, is responsible for induction of cancer stem cells and immune escape during",-0.13,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"enriched pathway for all drugs, is responsible for induction of cancer stem cells and immune escape during","enriched pathway for all drugs, is responsible for induction of cancer stem cells and immune escape during",cancer progression in various cancers such as head and neck squamous-cell carcinoma HNSC. Upregulation,cancer progression in various cancers such as head and neck squamous-cell carcinoma (HNSC). Upregulation,-0.13,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
cancer progression in various cancers such as head and neck squamous-cell carcinoma HNSC. Upregulation,cancer progression in various cancers such as head and neck squamous-cell carcinoma (HNSC). Upregulation,"of KRAS signaling, which is usually the second most enriched pathway, is also found to be associated with a","of KRAS signaling, which is usually the second most enriched pathway, is also found to be associated with a",-0.13,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"of KRAS signaling, which is usually the second most enriched pathway, is also found to be associated with a","of KRAS signaling, which is usually the second most enriched pathway, is also found to be associated with a","number of types of cancers such as breast cancer and pancreatic cancer. Therefore, we claim that the proposed","number of types of cancers such as breast cancer and pancreatic cancer. Therefore, we claim that the proposed",-0.13,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
"number of types of cancers such as breast cancer and pancreatic cancer. Therefore, we claim that the proposed","number of types of cancers such as breast cancer and pancreatic cancer. Therefore, we claim that the proposed",method has the capability of capturing drug reaction mechanism and thus generating trustworthy prediction of,method has the capability of capturing drug reaction mechanism and thus generating trustworthy prediction of,-0.13,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
method has the capability of capturing drug reaction mechanism and thus generating trustworthy prediction of,method has the capability of capturing drug reaction mechanism and thus generating trustworthy prediction of,drug responses.,drug responses.,-0.13,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,3,3,1
drug responses.,drug responses.,Scientific Reports 2025 15:179 https://doi.org/10.1038/s41598-024-83090-3 10,| https://doi.org/10.1038/s41598-024-83090-3,1.57,69.94,0,0,1,9,8,-1,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,3,3,0
"Fig. 6 .  a  Saliency map of Sunitinib,  b  binding mode of Sunitinib with PDGFRA.","Fig. 6.  (a) Saliency map of Sunitinib, (b) binding mode of Sunitinib with PDGFRA.",Drug Gene Rank Saliency score,Saliency score,12.68,93.64,0,0,1,9,7,-2,1,1,1,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,4,4,0
Drug Gene Rank Saliency score,Saliency score,Afatinib ERBB3 60 0.29,Afatinib,0.94,-90.5,0,1,0,7,7,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,1,4,4,1
Afatinib ERBB3 60 0.29,Afatinib,Afatinib EGFR 78 0.26,Afatinib,1,0,1,0,0,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,4,4,1
Afatinib EGFR 78 0.26,Afatinib,Afatinib ERBB2 108 0.23,Afatinib,1,0,1,0,0,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,4,4,1
Afatinib ERBB2 108 0.23,Afatinib,Imatinib MYC 2 0.85,Imatinib,1,0,1,0,0,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,4,4,1
Imatinib MYC 2 0.85,Imatinib,Imatinib SFN 10 0.64,Imatinib,1,0,1,0,0,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,4,4,1
Imatinib SFN 10 0.64,Imatinib,Imatinib DDR1 16 0.56,Imatinib,1,0,1,0,0,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,4,4,1
Imatinib DDR1 16 0.56,Imatinib,Imatinib CDKN2A 23 0.54,Imatinib,1,0,1,0,0,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,4,4,1
Imatinib CDKN2A 23 0.54,Imatinib,Imatinib EGFR 31 0.47,Imatinib,1,0,1,0,0,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,4,4,1
Imatinib EGFR 31 0.47,Imatinib,Imatinib IKZF1 93 0.28,Imatinib,1,0,1,0,0,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,4,4,1
Imatinib IKZF1 93 0.28,Imatinib,Imatinib SMAD3 166 0.22,Imatinib,1,0,1,0,0,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,4,4,1
Imatinib SMAD3 166 0.22,Imatinib,Sunitinib NOS3 7 0.7,Sunitinib,1,0,1,0,0,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,4,4,1
Sunitinib NOS3 7 0.7,Sunitinib,Sunitinib EGFR 19 0.51,Sunitinib,1,0,1,0,0,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,4,4,1
Sunitinib EGFR 19 0.51,Sunitinib,Sunitinib FGFR2 47 0.36,Sunitinib,1,0,1,0,0,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,4,4,1
Sunitinib FGFR2 47 0.36,Sunitinib,Sunitinib HMOX1 76 0.3,Sunitinib,1,0,1,0,0,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,4,4,1
Sunitinib HMOX1 76 0.3,Sunitinib,Sunitinib PDGFA 113 0.27,Sunitinib,1,0,1,0,0,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,4,4,1
Sunitinib PDGFA 113 0.27,Sunitinib,Sunitinib ERBB2 198 0.19,Sunitinib,0.95,0,1,0,0,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,4,4,1
Sunitinib ERBB2 198 0.19,Sunitinib,"Table 4 . Top salient genes identified by XGDP when predicting drug responses for Dasatinib, Erlotinib and","Table 4.  Top salient genes identified by XGDP when predicting drug responses for Dasatinib, Erlotinib and",3.98,-3.14,1,0,0,7,9,2,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,4,4,0
"Table 4 . Top salient genes identified by XGDP when predicting drug responses for Dasatinib, Erlotinib and","Table 4.  Top salient genes identified by XGDP when predicting drug responses for Dasatinib, Erlotinib and",Ponatinib.,Ponatinib.,-0.48,0,1,0,0,9,9,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,4,4,1
Ponatinib.,Ponatinib.,Drug Term ES NES,Drug,-96.89,3.14,1,0,0,9,7,-2,0,0,1,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,1,4,4,1
Drug Term ES NES,Drug,HALLMARKKRASSIGNALINGUP 356.8 0.7,HALLMARK_KRAS_SIGNALING_UP,110.51,32.93,0,0,0,7,7,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,1,4,4,1
HALLMARKKRASSIGNALINGUP 356.8 0.7,HALLMARK_KRAS_SIGNALING_UP,HALLMARKEPITHELIALMESENCHYMALTRANSITION 350.5 0.68,HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION,1,0,1,0,1,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,4,4,1
HALLMARKEPITHELIALMESENCHYMALTRANSITION 350.5 0.68,HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION,Afatinib,Afatinib,1,-32.92,0,1,0,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,4,4,1
Afatinib,Afatinib,Imatinib,Imatinib,20.79,0,1,0,0,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,4,4,1
Imatinib,Imatinib,Sunitinib,Sunitinib,20.74,0,1,0,0,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,4,4,1
Sunitinib,Sunitinib,HALLMARKINFLAMMATORYRESPONSE 316.08 0.62,HALLMARK_INFLAMMATORY_RESPONSE,-53.37,32.92,0,0,1,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,4,4,1
HALLMARKINFLAMMATORYRESPONSE 316.08 0.62,HALLMARK_INFLAMMATORY_RESPONSE,HALLMARKALLOGRAFTREJECTION 268.76 0.52,HALLMARK_ALLOGRAFT_REJECTION,1,0,1,1,1,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,4,4,1
HALLMARKALLOGRAFTREJECTION 268.76 0.52,HALLMARK_ALLOGRAFT_REJECTION,HALLMARKAPICALJUNCTION 268.5 0.52,HALLMARK_APICAL_JUNCTION,1,0,1,1,0,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,4,4,1
HALLMARKAPICALJUNCTION 268.5 0.52,HALLMARK_APICAL_JUNCTION,HALLMARKEPITHELIALMESENCHYMALTRANSITION 343.83 0.73,HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION,1,0,1,0,1,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,4,4,1
HALLMARKEPITHELIALMESENCHYMALTRANSITION 343.83 0.73,HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION,HALLMARKKRASSIGNALINGUP 298.37 0.63,HALLMARK_KRAS_SIGNALING_UP,1,0,1,1,0,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,4,4,1
HALLMARKKRASSIGNALINGUP 298.37 0.63,HALLMARK_KRAS_SIGNALING_UP,HALLMARKAPICALJUNCTION 289.58 0.62,HALLMARK_APICAL_JUNCTION,1,0,1,0,0,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,4,4,1
HALLMARKAPICALJUNCTION 289.58 0.62,HALLMARK_APICAL_JUNCTION,HALLMARKMYOGENESIS 282.84 0.6,HALLMARK_MYOGENESIS,1,0,1,0,0,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,4,4,1
HALLMARKMYOGENESIS 282.84 0.6,HALLMARK_MYOGENESIS,HALLMARKTNFASIGNALINGVIANFKB 280.9 0.6,HALLMARK_TNFA_SIGNALING_VIA_NFKB,1,0,1,0,1,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,4,4,1
HALLMARKTNFASIGNALINGVIANFKB 280.9 0.6,HALLMARK_TNFA_SIGNALING_VIA_NFKB,HALLMARKEPITHELIALMESENCHYMALTRANSITION 345.81 0.73,HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION,1,0,1,1,1,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,4,4,1
HALLMARKEPITHELIALMESENCHYMALTRANSITION 345.81 0.73,HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION,HALLMARKKRASSIGNALINGUP 307.34 0.65,HALLMARK_KRAS_SIGNALING_UP,1,0,1,1,0,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,4,4,1
HALLMARKKRASSIGNALINGUP 307.34 0.65,HALLMARK_KRAS_SIGNALING_UP,HALLMARKAPICALJUNCTION 290.69 0.61,HALLMARK_APICAL_JUNCTION,1,0,1,0,0,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,4,4,1
HALLMARKAPICALJUNCTION 290.69 0.61,HALLMARK_APICAL_JUNCTION,HALLMARKTNFASIGNALINGVIANFKB 277.54 0.59,HALLMARK_TNFA_SIGNALING_VIA_NFKB,1,0,1,0,1,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,4,4,1
HALLMARKTNFASIGNALINGVIANFKB 277.54 0.59,HALLMARK_TNFA_SIGNALING_VIA_NFKB,HALLMARKUVRESPONSEDN 264.91 0.56,HALLMARK_UV_RESPONSE_DN,0.95,0,1,1,0,7,7,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,4,4,1
HALLMARKUVRESPONSEDN 264.91 0.56,HALLMARK_UV_RESPONSE_DN,Table 5 . Enriched pathways from GSEA on attributed saliency scores.,Table 5.  Enriched pathways from GSEA on attributed saliency scores.,3.98,-36.07,0,0,0,7,9,2,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,4,4,0
Table 5 . Enriched pathways from GSEA on attributed saliency scores.,Table 5.  Enriched pathways from GSEA on attributed saliency scores.,Scientific Reports 2025 15:179 https://doi.org/10.1038/s41598-024-83090-3 11,| https://doi.org/10.1038/s41598-024-83090-3,10.32,69.94,0,0,1,9,8,-1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,4,4,0
Conclusion,Conclusion,This study introduced a novel framework XGDP to predict response levels of anti-cancer drugs and discover,This study introduced a novel framework XGDP to predict response levels of anti-cancer drugs and discover,-0.11,0,1,0,0,11,9,-2,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,5,5,0
This study introduced a novel framework XGDP to predict response levels of anti-cancer drugs and discover,This study introduced a novel framework XGDP to predict response levels of anti-cancer drugs and discover,"underlying mechanism of action of drugs. To enhance the predictive power of GNN models, first we adapted","underlying mechanism of action of drugs. To enhance the predictive power of GNN models, first we adapted",-0.16,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,5,5,1
"underlying mechanism of action of drugs. To enhance the predictive power of GNN models, first we adapted","underlying mechanism of action of drugs. To enhance the predictive power of GNN models, first we adapted",the Morgan algorithm that is used for computing ECFPs to form our node features. Same procedures as Morgan,the Morgan algorithm that is used for computing ECFPs to form our node features. Same procedures as Morgan,-0.16,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,5,5,1
the Morgan algorithm that is used for computing ECFPs to form our node features. Same procedures as Morgan,the Morgan algorithm that is used for computing ECFPs to form our node features. Same procedures as Morgan,algorithm were followed to identify the substructures of the molecule but the feature vector of each atom was,algorithm were followed to identify the substructures of the molecule but the feature vector of each atom was,-0.16,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,5,5,1
algorithm were followed to identify the substructures of the molecule but the feature vector of each atom was,algorithm were followed to identify the substructures of the molecule but the feature vector of each atom was,assigned as the membership of the identified structures. Then we incorporated the type of chemical bonds as the,assigned as the membership of the identified structures. Then we incorporated the type of chemical bonds as the,-0.16,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,5,5,1
assigned as the membership of the identified structures. Then we incorporated the type of chemical bonds as the,assigned as the membership of the identified structures. Then we incorporated the type of chemical bonds as the,edge features. These strategies enabled us to depict the molecule in a more meticulous manner and was testified,edge features. These strategies enabled us to depict the molecule in a more meticulous manner and was testified,-0.16,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,5,5,1
edge features. These strategies enabled us to depict the molecule in a more meticulous manner and was testified,edge features. These strategies enabled us to depict the molecule in a more meticulous manner and was testified,"to improve the GNN’s prediction in terms of RMSE and PCC. Furthermore, we also attempted to explore","to improve the GNN’s prediction in terms of RMSE and PCC. Furthermore, we also attempted to explore",-0.16,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,5,5,1
"to improve the GNN’s prediction in terms of RMSE and PCC. Furthermore, we also attempted to explore","to improve the GNN’s prediction in terms of RMSE and PCC. Furthermore, we also attempted to explore","relational GNN in the drug response prediction task, which describes edges as different relations and develops","relational GNN in the drug response prediction task, which describes edges as different relations and develops",-0.16,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,5,5,1
"relational GNN in the drug response prediction task, which describes edges as different relations and develops","relational GNN in the drug response prediction task, which describes edges as different relations and develops",distinct message passing patterns for them. It was shown that RGCN outperformed GCN without edge features.,distinct message passing patterns for them. It was shown that RGCN outperformed GCN without edge features.,-0.16,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,5,5,1
distinct message passing patterns for them. It was shown that RGCN outperformed GCN without edge features.,distinct message passing patterns for them. It was shown that RGCN outperformed GCN without edge features.,"However, due to the limited GPU resources, we were not able to train the RGAT model with an optimal batch","However, due to the limited GPU resources, we were not able to train the RGAT model with an optimal batch",-0.16,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,5,5,1
"However, due to the limited GPU resources, we were not able to train the RGAT model with an optimal batch","However, due to the limited GPU resources, we were not able to train the RGAT model with an optimal batch",size. This part of experiments is left for future investigations.,size. This part of experiments is left for future investigations.,-0.16,0,1,0,1,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,5,5,1
size. This part of experiments is left for future investigations.,size. This part of experiments is left for future investigations.,"Moreover, we leveraged state-of-the-art attribution approaches in deep learning, GNNExplainer and","Moreover, we leveraged state-of-the-art attribution approaches in deep learning, GNNExplainer and",-0.16,12,0,1,0,9,9,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,5,5,0
"Moreover, we leveraged state-of-the-art attribution approaches in deep learning, GNNExplainer and","Moreover, we leveraged state-of-the-art attribution approaches in deep learning, GNNExplainer and","Integrated Gradients, to explain our developed model. The explanations were visualized as saliency maps of","Integrated Gradients, to explain our developed model. The explanations were visualized as saliency maps of",-0.16,-12,0,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,5,5,1
"Integrated Gradients, to explain our developed model. The explanations were visualized as saliency maps of","Integrated Gradients, to explain our developed model. The explanations were visualized as saliency maps of","both molecules and genes. Remarkably, those saliency maps could be supported by the SAR studies of the drugs.","both molecules and genes. Remarkably, those saliency maps could be supported by the SAR studies of the drugs.",-0.16,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,5,5,1
"both molecules and genes. Remarkably, those saliency maps could be supported by the SAR studies of the drugs.","both molecules and genes. Remarkably, those saliency maps could be supported by the SAR studies of the drugs.","Consequently, we claim that our model is able to capture the significant functional groups of drugs and their","Consequently, we claim that our model is able to capture the significant functional groups of drugs and their",-0.16,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,5,5,1
"Consequently, we claim that our model is able to capture the significant functional groups of drugs and their","Consequently, we claim that our model is able to capture the significant functional groups of drugs and their","potential targeted genes, and thus reveal the comprehensive mechanism of action of drugs. In the future, we","potential targeted genes, and thus reveal the comprehensive mechanism of action of drugs. In the future, we",-0.16,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,5,5,1
"potential targeted genes, and thus reveal the comprehensive mechanism of action of drugs. In the future, we","potential targeted genes, and thus reveal the comprehensive mechanism of action of drugs. In the future, we",intend to extend this study to a multi-omics level. Although genes contain the most vital information of the,intend to extend this study to a multi-omics level. Although genes contain the most vital information of the,-0.16,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,5,5,1
intend to extend this study to a multi-omics level. Although genes contain the most vital information of the,intend to extend this study to a multi-omics level. Although genes contain the most vital information of the,"cause of disease, they do not directly interact with drugs in most cases. Therefore, protein and metabolites data","cause of disease, they do not directly interact with drugs in most cases. Therefore, protein and metabolites data",-0.16,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,5,5,1
"cause of disease, they do not directly interact with drugs in most cases. Therefore, protein and metabolites data","cause of disease, they do not directly interact with drugs in most cases. Therefore, protein and metabolites data","should be considered. In addition, gene mutation and DNA methylation data may have a more direct reflection","should be considered. In addition, gene mutation and DNA methylation data may have a more direct reflection",-0.16,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,5,5,1
"should be considered. In addition, gene mutation and DNA methylation data may have a more direct reflection","should be considered. In addition, gene mutation and DNA methylation data may have a more direct reflection","on the somatic abnormality, which are also expected to be explored in future works.","on the somatic abnormality, which are also expected to be explored in future works.",-0.16,0,1,0,1,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,5,5,1
"on the somatic abnormality, which are also expected to be explored in future works.","on the somatic abnormality, which are also expected to be explored in future works.",Data Availability,Data Availability,0.61,0,1,1,0,9,11,2,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,5,5,0
Data Availability,Data Availability,The drug response data can be downloaded from GDSC. And the gene expression data can be downloaded fromhttps://www.cancerrxgene.org/downloads/drugdata,The drug response data can be downloaded from GDSC. And the gene expression data can be downloaded from,-0.11,0,1,0,0,11,9,-2,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,5,5,0
The drug response data can be downloaded from GDSC. And the gene expression data can be downloaded fromhttps://www.cancerrxgene.org/downloads/drugdata,The drug response data can be downloaded from GDSC. And the gene expression data can be downloaded from,CCLE under mRNA expression. Our implementation is released on Github ?https://depmap.org/portal/download/all/ ? h?t?t?p ? s?:?/?/?g?i ? t?h?u?b?.?c ? o?m?/?S?C?Shttps://github.com/SCSE-Biomedical-Computing-Group/XGDP ? E?-?B?i?o?m?e?d?i?,CCLE under mRNA expression. Our implementation is released on Github ?(?h?t?t?p?s?:?/?/?g?i?t?h?u?b?.?c?o?m?/?S?C?S?E?-?B?i?o?m?e?d?i?,-0.16,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,5,5,1
CCLE under mRNA expression. Our implementation is released on Github ?https://depmap.org/portal/download/all/ ? h?t?t?p ? s?:?/?/?g?i ? t?h?u?b?.?c ? o?m?/?S?C?Shttps://github.com/SCSE-Biomedical-Computing-Group/XGDP ? E?-?B?i?o?m?e?d?i?,CCLE under mRNA expression. Our implementation is released on Github ?(?h?t?t?p?s?:?/?/?g?i?t?h?u?b?.?c?o?m?/?S?C?S?E?-?B?i?o?m?e?d?i?,c?a?l?-?C?o?m?p?u?t?i?n?g?-?G?r?o?u?p?/?X?G?D?P?. Data preprocessing can be referred to our codes.https://github.com/SCSE-Biomedical-Computing-Group/XGDP ?,c?a?l?-?C?o?m?p?u?t?i?n?g?-?G?r?o?u?p?/?X?G?D?P?)?. Data preprocessing can be referred to our codes.,-0.16,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,5,5,1
c?a?l?-?C?o?m?p?u?t?i?n?g?-?G?r?o?u?p?/?X?G?D?P?. Data preprocessing can be referred to our codes.https://github.com/SCSE-Biomedical-Computing-Group/XGDP ?,c?a?l?-?C?o?m?p?u?t?i?n?g?-?G?r?o?u?p?/?X?G?D?P?)?. Data preprocessing can be referred to our codes.,Received: 16 June 2024; Accepted: 11 December 2024,Received: 16 June 2024; Accepted: 11 December 2024,0.65,0,1,0,1,9,8.5,-0.5,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,5,5,0
Received: 16 June 2024; Accepted: 11 December 2024,Received: 16 June 2024; Accepted: 11 December 2024,References,References,1.53,0,1,1,0,8.5,11,2.5,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,5,5,0
References,References,"1. Singh, D. P. & Kaushik, B. A systematic literature review for the prediction of anticancer drug response using various machine","1.	 Singh, D. P. & Kaushik, B. A systematic literature review for the prediction of anticancer drug response using various machine",-0.12,0,1,0,0,11,7.5,-3.5,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,5,5,0
"1. Singh, D. P. & Kaushik, B. A systematic literature review for the prediction of anticancer drug response using various machine","1.	 Singh, D. P. & Kaushik, B. A systematic literature review for the prediction of anticancer drug response using various machine",learning and deep learning techniques. Chem. Biol. Drug Des. 2022.,learning and deep learning techniques. Chem. Biol. Drug Des. (2022).,-0.13,12.76,0,0,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,5,5,1
learning and deep learning techniques. Chem. Biol. Drug Des. 2022.,learning and deep learning techniques. Chem. Biol. Drug Des. (2022).,"2. Rafique, R., Islam, S. R. & Kazi, J. U. Machine learning in the prediction of cancer therapy. Comput. Struct. Biotechnol. J. 19,","2.	 Rafique, R., Islam, S. R. & Kazi, J. U. Machine learning in the prediction of cancer therapy. Comput. Struct. Biotechnol. J. 19,",-0.13,-12.76,0,0,1,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,5,5,1
"2. Rafique, R., Islam, S. R. & Kazi, J. U. Machine learning in the prediction of cancer therapy. Comput. Struct. Biotechnol. J. 19,","2.	 Rafique, R., Islam, S. R. & Kazi, J. U. Machine learning in the prediction of cancer therapy. Comput. Struct. Biotechnol. J. 19,",4003–4017 2021.,4003–4017 (2021).,-0.13,12.76,0,1,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,5,5,1
4003–4017 2021.,4003–4017 (2021).,"3. Firoozbakht, F., Yousefi, B. & Schwikowski, B. An overview of machine learning methods for monotherapy drug response","3.	 Firoozbakht, F., Yousefi, B. & Schwikowski, B. An overview of machine learning methods for monotherapy drug response",-0.13,-12.76,0,0,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,5,5,1
"3. Firoozbakht, F., Yousefi, B. & Schwikowski, B. An overview of machine learning methods for monotherapy drug response","3.	 Firoozbakht, F., Yousefi, B. & Schwikowski, B. An overview of machine learning methods for monotherapy drug response","prediction. Brief. Bioinform. 23, bbab408 2022.","prediction. Brief. Bioinform. 23, bbab408 (2022).",-0.13,12.76,0,0,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,5,5,1
"prediction. Brief. Bioinform. 23, bbab408 2022.","prediction. Brief. Bioinform. 23, bbab408 (2022).","4. Baptista, D., Ferreira, P. G. & Rocha, M. Deep learning for drug response prediction in cancer. Brief. Bioinform. 22, 360–379 2021.","4.	 Baptista, D., Ferreira, P. G. & Rocha, M. Deep learning for drug response prediction in cancer. Brief. Bioinform. 22, 360–379 (2021).",-0.13,-12.76,0,0,1,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,5,5,1
"4. Baptista, D., Ferreira, P. G. & Rocha, M. Deep learning for drug response prediction in cancer. Brief. Bioinform. 22, 360–379 2021.","4.	 Baptista, D., Ferreira, P. G. & Rocha, M. Deep learning for drug response prediction in cancer. Brief. Bioinform. 22, 360–379 (2021).","5. Partin, A. et al. Deep learning methods for drug response prediction in cancer: Predominant and emerging trends. arXiv preprint","5.	 Partin, A. et al. Deep learning methods for drug response prediction in cancer: Predominant and emerging trends. arXiv preprint",-0.13,0,1,1,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,5,5,1
"5. Partin, A. et al. Deep learning methods for drug response prediction in cancer: Predominant and emerging trends. arXiv preprint","5.	 Partin, A. et al. Deep learning methods for drug response prediction in cancer: Predominant and emerging trends. arXiv preprint",arXiv:2211.10442 2022.http://arxiv.org/abs/2211.10442,arXiv:2211.10442 (2022).,-0.13,12.76,0,0,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,5,5,1
arXiv:2211.10442 2022.http://arxiv.org/abs/2211.10442,arXiv:2211.10442 (2022).,"6. Moffat, J. G., Vincent, F., Lee, J. A., Eder, J. & Prunotto, M. Opportunities and challenges in phenotypic drug discovery: An industry","6.	 Moffat, J. G., Vincent, F., Lee, J. A., Eder, J. & Prunotto, M. Opportunities and challenges in phenotypic drug discovery: An industry",-0.13,-12.76,0,0,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,5,5,1
"6. Moffat, J. G., Vincent, F., Lee, J. A., Eder, J. & Prunotto, M. Opportunities and challenges in phenotypic drug discovery: An industry","6.	 Moffat, J. G., Vincent, F., Lee, J. A., Eder, J. & Prunotto, M. Opportunities and challenges in phenotypic drug discovery: An industry","perspective. Nat. Rev. Drug Discov. 16, 531–543 2017.","perspective. Nat. Rev. Drug Discov. 16, 531–543 (2017).",-0.13,12.76,0,0,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,5,5,1
"perspective. Nat. Rev. Drug Discov. 16, 531–543 2017.","perspective. Nat. Rev. Drug Discov. 16, 531–543 (2017).","7. An, X., Chen, X., Yi, D., Li, H. & Guan, Y. Representation of molecules for drug response prediction. Brief. Bioinform. 23, bbab393","7.	 An, X., Chen, X., Yi, D., Li, H. & Guan, Y. Representation of molecules for drug response prediction. Brief. Bioinform. 23, bbab393",-0.13,-12.76,0,0,1,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,5,5,1
"7. An, X., Chen, X., Yi, D., Li, H. & Guan, Y. Representation of molecules for drug response prediction. Brief. Bioinform. 23, bbab393","7.	 An, X., Chen, X., Yi, D., Li, H. & Guan, Y. Representation of molecules for drug response prediction. Brief. Bioinform. 23, bbab393",2022,(2022).,-0.13,12.76,0,1,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,5,5,1
2022,(2022).,"8. Heller, S. R., McNaught, A., Pletnev, I., Stein, S. & Tchekhovskoi, D. InChI, the IUPAC international chemical identifier. J.","8.	 Heller, S. R., McNaught, A., Pletnev, I., Stein, S. & Tchekhovskoi, D. InChI, the IUPAC international chemical identifier. J.",-0.13,-12.76,0,0,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,5,5,1
"8. Heller, S. R., McNaught, A., Pletnev, I., Stein, S. & Tchekhovskoi, D. InChI, the IUPAC international chemical identifier. J.","8.	 Heller, S. R., McNaught, A., Pletnev, I., Stein, S. & Tchekhovskoi, D. InChI, the IUPAC international chemical identifier. J.","Cheminform. 7, 1–34 2015.","Cheminform. 7, 1–34 (2015).",-0.13,12.76,0,0,0,7.5,7.5,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,5,5,1
"Cheminform. 7, 1–34 2015.","Cheminform. 7, 1–34 (2015).","9. Weininger, D. Smiles. A chemical language and information system 1 introduction to methodology and encoding rules. J. Chem.","9.	 Weininger, D. Smiles. A chemical language and information system 1 introduction to methodology and encoding rules. J. Chem.",-0.13,-12.76,0,0,1,7.5,7.5,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,5,5,1
"9. Weininger, D. Smiles. A chemical language and information system 1 introduction to methodology and encoding rules. J. Chem.","9.	 Weininger, D. Smiles. A chemical language and information system 1 introduction to methodology and encoding rules. J. Chem.","Inf. Comput. Sci. 28, 31–36 1988.","Inf. Comput. Sci. 28, 31–36 (1988).",-0.13,12.76,0,1,0,7.5,7.5,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,5,5,1
"Inf. Comput. Sci. 28, 31–36 1988.","Inf. Comput. Sci. 28, 31–36 (1988).","10. Suphavilai, C., Bertrand, D. & Nagarajan, N. Predicting cancer drug response using a recommender system. Bioinformatics 34,","10.	 Suphavilai, C., Bertrand, D. & Nagarajan, N. Predicting cancer drug response using a recommender system. Bioinformatics 34,",-0.13,-12.76,0,0,1,7.5,7.5,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,5,5,1
"10. Suphavilai, C., Bertrand, D. & Nagarajan, N. Predicting cancer drug response using a recommender system. Bioinformatics 34,","10.	 Suphavilai, C., Bertrand, D. & Nagarajan, N. Predicting cancer drug response using a recommender system. Bioinformatics 34,",3907–3914 2018.,3907–3914 (2018).,-0.13,12.76,0,1,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,5,5,1
3907–3914 2018.,3907–3914 (2018).,"11. Liu, P., Li, H., Li, S. & Leung, K.-S. Improving prediction of phenotypic drug response on cancer cell lines using deep convolutional","11.	 Liu, P., Li, H., Li, S. & Leung, K.-S. Improving prediction of phenotypic drug response on cancer cell lines using deep convolutional",-0.13,-12.76,0,0,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,5,5,1
"11. Liu, P., Li, H., Li, S. & Leung, K.-S. Improving prediction of phenotypic drug response on cancer cell lines using deep convolutional","11.	 Liu, P., Li, H., Li, S. & Leung, K.-S. Improving prediction of phenotypic drug response on cancer cell lines using deep convolutional","network. BMC Bioinform. 20, 1–14 2019.","network. BMC Bioinform. 20, 1–14 (2019).",-0.13,12.76,0,0,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,5,5,1
"network. BMC Bioinform. 20, 1–14 2019.","network. BMC Bioinform. 20, 1–14 (2019).","12. Chang, Y. et al. Cancer drug response profile scan CDRscan: A deep learning model that predicts drug effectiveness from cancer","12.	 Chang, Y. et al. Cancer drug response profile scan (CDRscan): A deep learning model that predicts drug effectiveness from cancer",-0.13,-12.76,0,0,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,5,5,1
"12. Chang, Y. et al. Cancer drug response profile scan CDRscan: A deep learning model that predicts drug effectiveness from cancer","12.	 Chang, Y. et al. Cancer drug response profile scan (CDRscan): A deep learning model that predicts drug effectiveness from cancer","genomic signature. Sci. Rep. 8, 1–11 2018.","genomic signature. Sci. Rep. 8, 1–11 (2018).",-0.13,12.76,0,0,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,5,5,1
"genomic signature. Sci. Rep. 8, 1–11 2018.","genomic signature. Sci. Rep. 8, 1–11 (2018).","13. Durant, J. L., Leland, B. A., Henry, D. R. & Nourse, J. G. Reoptimization of MDL keys for use in drug discovery. J. Chem. Inf.","13.	 Durant, J. L., Leland, B. A., Henry, D. R. & Nourse, J. G. Reoptimization of MDL keys for use in drug discovery. J. Chem. Inf.",-0.13,-12.76,0,0,1,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,5,5,1
"13. Durant, J. L., Leland, B. A., Henry, D. R. & Nourse, J. G. Reoptimization of MDL keys for use in drug discovery. J. Chem. Inf.","13.	 Durant, J. L., Leland, B. A., Henry, D. R. & Nourse, J. G. Reoptimization of MDL keys for use in drug discovery. J. Chem. Inf.","Comput. Sci. 42, 1273–1280 2002.","Comput. Sci. 42, 1273–1280 (2002).",-0.13,12.76,0,1,0,7.5,7.5,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,5,5,1
"Comput. Sci. 42, 1273–1280 2002.","Comput. Sci. 42, 1273–1280 (2002).","14. Reutlinger, M. et al. Chemically advanced template search cats for scaffold-hopping and prospective target prediction for","14.	 Reutlinger, M. et al. Chemically advanced template search (cats) for scaffold-hopping and prospective target prediction for",-0.13,-12.76,0,0,0,7.5,7.5,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,5,5,1
"14. Reutlinger, M. et al. Chemically advanced template search cats for scaffold-hopping and prospective target prediction for","14.	 Reutlinger, M. et al. Chemically advanced template search (cats) for scaffold-hopping and prospective target prediction for","‘orphan’molecules. Mol. Inf. 32, 133 2013.","‘orphan’molecules. Mol. Inf. 32, 133 (2013).",-0.13,12.76,0,0,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,5,5,1
"‘orphan’molecules. Mol. Inf. 32, 133 2013.","‘orphan’molecules. Mol. Inf. 32, 133 (2013).","15. Rogers, D. & Hahn, M. Extended-connectivity fingerprints. J. Chem. Inf. Model. 50, 742–754 2010.","15.	 Rogers, D. & Hahn, M. Extended-connectivity fingerprints. J. Chem. Inf. Model. 50, 742–754 (2010).",-0.13,-12.76,0,0,1,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,5,5,1
"15. Rogers, D. & Hahn, M. Extended-connectivity fingerprints. J. Chem. Inf. Model. 50, 742–754 2010.","15.	 Rogers, D. & Hahn, M. Extended-connectivity fingerprints. J. Chem. Inf. Model. 50, 742–754 (2010).","16. Li, M. et al. DeepDsc: A deep learning method to predict drug sensitivity of cancer cell lines. IEEE/ACM Trans. Comput. Biol.","16.	 Li, M. et al. DeepDsc: A deep learning method to predict drug sensitivity of cancer cell lines. IEEE/ACM Trans. Comput. Biol.",-0.13,0,1,1,1,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,5,5,1
"16. Li, M. et al. DeepDsc: A deep learning method to predict drug sensitivity of cancer cell lines. IEEE/ACM Trans. Comput. Biol.","16.	 Li, M. et al. DeepDsc: A deep learning method to predict drug sensitivity of cancer cell lines. IEEE/ACM Trans. Comput. Biol.","Bioinform. 18, 575–582 2019.","Bioinform. 18, 575–582 (2019).",-0.13,12.76,0,1,0,7.5,7.5,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,5,5,1
"Bioinform. 18, 575–582 2019.","Bioinform. 18, 575–582 (2019).","17. Shao, J. et al. S2dv: Converting smiles to a drug vector for predicting the activity of anti-HBV small molecules. Brief. Bioinform. 23,","17.	 Shao, J. et al. S2dv: Converting smiles to a drug vector for predicting the activity of anti-HBV small molecules. Brief. Bioinform. 23,",-0.13,-12.76,0,0,1,7.5,7.5,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,5,5,1
"17. Shao, J. et al. S2dv: Converting smiles to a drug vector for predicting the activity of anti-HBV small molecules. Brief. Bioinform. 23,","17.	 Shao, J. et al. S2dv: Converting smiles to a drug vector for predicting the activity of anti-HBV small molecules. Brief. Bioinform. 23,",593 2022.,593 (2022).,-0.13,12.76,0,1,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,5,5,1
593 2022.,593 (2022).,"18. Mikolov, T., Chen, K., Corrado, G. & Dean, J. Efficient estimation of word representations in vector space. arXiv preprint","18.	 Mikolov, T., Chen, K., Corrado, G. & Dean, J. Efficient estimation of word representations in vector space. arXiv preprint",-0.13,-12.76,0,0,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,5,5,1
"18. Mikolov, T., Chen, K., Corrado, G. & Dean, J. Efficient estimation of word representations in vector space. arXiv preprint","18.	 Mikolov, T., Chen, K., Corrado, G. & Dean, J. Efficient estimation of word representations in vector space. arXiv preprint",arXiv:1301.3781 2013.http://arxiv.org/abs/1301.3781,arXiv:1301.3781 (2013).,-0.13,12.76,0,0,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,5,5,1
arXiv:1301.3781 2013.http://arxiv.org/abs/1301.3781,arXiv:1301.3781 (2013).,"19. Ma, J., Sheridan, R. P., Liaw, A., Dahl, G. E. & Svetnik, V. Deep neural nets as a method for quantitative structure-activity","19.	 Ma, J., Sheridan, R. P., Liaw, A., Dahl, G. E. & Svetnik, V. Deep neural nets as a method for quantitative structure-activity",-0.13,-12.76,0,0,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,5,5,1
"19. Ma, J., Sheridan, R. P., Liaw, A., Dahl, G. E. & Svetnik, V. Deep neural nets as a method for quantitative structure-activity","19.	 Ma, J., Sheridan, R. P., Liaw, A., Dahl, G. E. & Svetnik, V. Deep neural nets as a method for quantitative structure-activity","relationships. J. Chem. Inf. Model. 55, 263–274 2015.","relationships. J. Chem. Inf. Model. 55, 263–274 (2015).",-0.13,12.76,0,0,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,5,5,1
"relationships. J. Chem. Inf. Model. 55, 263–274 2015.","relationships. J. Chem. Inf. Model. 55, 263–274 (2015).","20. Sun, M. et al. Graph convolutional networks for computational drug development and discovery. Brief. Bioinform. 21, 919–935","20.	 Sun, M. et al. Graph convolutional networks for computational drug development and discovery. Brief. Bioinform. 21, 919–935",-0.13,-12.76,0,0,1,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,5,5,1
"20. Sun, M. et al. Graph convolutional networks for computational drug development and discovery. Brief. Bioinform. 21, 919–935","20.	 Sun, M. et al. Graph convolutional networks for computational drug development and discovery. Brief. Bioinform. 21, 919–935",2020,(2020).,-0.13,12.76,0,1,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,5,5,1
2020,(2020).,"21. Hu, L. et al. Dual-channel hypergraph convolutional network for predicting herb-disease associations. Brief. Bioinform. 25,","21.	 Hu, L. et al. Dual-channel hypergraph convolutional network for predicting herb-disease associations. Brief. Bioinform. 25,",-0.13,-12.76,0,0,1,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,5,5,1
"21. Hu, L. et al. Dual-channel hypergraph convolutional network for predicting herb-disease associations. Brief. Bioinform. 25,","21.	 Hu, L. et al. Dual-channel hypergraph convolutional network for predicting herb-disease associations. Brief. Bioinform. 25,",bbae067 2024.,bbae067 (2024).,-0.13,12.76,0,1,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,5,5,1
bbae067 2024.,bbae067 (2024).,"22. Zhao, B.-W. et al. A geometric deep learning framework for drug repositioning over heterogeneous information networks. Brief.","22.	 Zhao, B.-W. et al. A geometric deep learning framework for drug repositioning over heterogeneous information networks. Brief.",-0.13,-12.76,0,0,1,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,5,5,1
"22. Zhao, B.-W. et al. A geometric deep learning framework for drug repositioning over heterogeneous information networks. Brief.","22.	 Zhao, B.-W. et al. A geometric deep learning framework for drug repositioning over heterogeneous information networks. Brief.","Bioinform. 23, bbac384 2022.","Bioinform. 23, bbac384 (2022).",-0.13,12.76,0,1,0,7.5,7.5,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,5,5,1
"Bioinform. 23, bbac384 2022.","Bioinform. 23, bbac384 (2022).","23. Korolev, V., Mitrofanov, A., Korotcov, A. & Tkachenko, V. Graph convolutional neural networks as “general-purpose’’ property","23.	 Korolev, V., Mitrofanov, A., Korotcov, A. & Tkachenko, V. Graph convolutional neural networks as “general-purpose’’ property",-0.13,-12.76,0,0,0,7.5,7.5,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,5,5,1
"23. Korolev, V., Mitrofanov, A., Korotcov, A. & Tkachenko, V. Graph convolutional neural networks as “general-purpose’’ property","23.	 Korolev, V., Mitrofanov, A., Korotcov, A. & Tkachenko, V. Graph convolutional neural networks as “general-purpose’’ property","predictors: The universality and limits of applicability. J. Chem. Inf. Model. 60, 22–28 2019.","predictors: The universality and limits of applicability. J. Chem. Inf. Model. 60, 22–28 (2019).",-0.13,12.76,0,0,1,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,5,5,1
"predictors: The universality and limits of applicability. J. Chem. Inf. Model. 60, 22–28 2019.","predictors: The universality and limits of applicability. J. Chem. Inf. Model. 60, 22–28 (2019).",Scientific Reports 2025 15:179 https://doi.org/10.1038/s41598-024-83090-3 12,| https://doi.org/10.1038/s41598-024-83090-3,1.35,57.19,0,1,1,7.5,8,0.5,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,5,5,1
"24. Xiong, Z. et al. Pushing the boundaries of molecular representation for drug discovery with the graph attention mechanism. J. Med.","24.	 Xiong, Z. et al. Pushing the boundaries of molecular representation for drug discovery with the graph attention mechanism. J. Med.","Chem. 63, 8749–8760 2019.","Chem. 63, 8749–8760 (2019).",-0.21,12.76,0,1,0,7.5,7.5,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"Chem. 63, 8749–8760 2019.","Chem. 63, 8749–8760 (2019).","25. Nguyen, T., Nguyen, G. T., Nguyen, T. & Le, D.-H. Graph convolutional networks for drug response prediction. IEEE/ACM Trans.","25.	 Nguyen, T., Nguyen, G. T., Nguyen, T. & Le, D.-H. Graph convolutional networks for drug response prediction. IEEE/ACM Trans.",-0.19,-12.76,0,0,1,7.5,7.5,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"25. Nguyen, T., Nguyen, G. T., Nguyen, T. & Le, D.-H. Graph convolutional networks for drug response prediction. IEEE/ACM Trans.","25.	 Nguyen, T., Nguyen, G. T., Nguyen, T. & Le, D.-H. Graph convolutional networks for drug response prediction. IEEE/ACM Trans.","Comput. Biol. Bioinform. 19, 146–154 2021.","Comput. Biol. Bioinform. 19, 146–154 (2021).",-0.21,12.76,0,1,0,7.5,7.5,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"Comput. Biol. Bioinform. 19, 146–154 2021.","Comput. Biol. Bioinform. 19, 146–154 (2021).","26. Liu, Q., Hu, Z., Jiang, R. & Zhou, M. DeepCDR: A hybrid graph convolutional network for predicting cancer drug response.","26.	 Liu, Q., Hu, Z., Jiang, R. & Zhou, M. DeepCDR: A hybrid graph convolutional network for predicting cancer drug response.",-0.19,-12.76,0,0,0,7.5,7.5,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"26. Liu, Q., Hu, Z., Jiang, R. & Zhou, M. DeepCDR: A hybrid graph convolutional network for predicting cancer drug response.","26.	 Liu, Q., Hu, Z., Jiang, R. & Zhou, M. DeepCDR: A hybrid graph convolutional network for predicting cancer drug response.","Bioinformatics 36, i911–i918 2020.","Bioinformatics 36, i911–i918 (2020).",-0.21,12.76,0,0,0,7.5,7.5,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"Bioinformatics 36, i911–i918 2020.","Bioinformatics 36, i911–i918 (2020).","27. Zhu, Y. et al. TGSA: Protein–Protein association-based twin graph neural networks for drug response prediction with similarity","27.	 Zhu, Y. et al. TGSA: Protein–Protein association-based twin graph neural networks for drug response prediction with similarity",-0.19,-12.76,0,0,0,7.5,7.5,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"27. Zhu, Y. et al. TGSA: Protein–Protein association-based twin graph neural networks for drug response prediction with similarity","27.	 Zhu, Y. et al. TGSA: Protein–Protein association-based twin graph neural networks for drug response prediction with similarity","augmentation. Bioinformatics 38, 461–468 2022.","augmentation. Bioinformatics 38, 461–468 (2022).",-0.19,12.76,0,0,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,6,6,1
"augmentation. Bioinformatics 38, 461–468 2022.","augmentation. Bioinformatics 38, 461–468 (2022).","28. Ma, T. et al. DualGCN: A dual graph convolutional network model to predict cancer drug response. BMC Bioinform. 23, 129","28.	 Ma, T. et al. DualGCN: A dual graph convolutional network model to predict cancer drug response. BMC Bioinform. 23, 129",-0.19,-12.76,0,0,1,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"28. Ma, T. et al. DualGCN: A dual graph convolutional network model to predict cancer drug response. BMC Bioinform. 23, 129","28.	 Ma, T. et al. DualGCN: A dual graph convolutional network model to predict cancer drug response. BMC Bioinform. 23, 129",2022,(2022).,-0.19,12.76,0,1,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,6,6,1
2022,(2022).,"29. Zuo, Z. et al. SWnet: A deep learning model for drug response prediction from cancer genomic signatures and compound chemical","29.	 Zuo, Z. et al. SWnet: A deep learning model for drug response prediction from cancer genomic signatures and compound chemical",-0.19,-12.76,0,0,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"29. Zuo, Z. et al. SWnet: A deep learning model for drug response prediction from cancer genomic signatures and compound chemical","29.	 Zuo, Z. et al. SWnet: A deep learning model for drug response prediction from cancer genomic signatures and compound chemical","structures. BMC Bioinform. 22, 1–16 2021.","structures. BMC Bioinform. 22, 1–16 (2021).",-0.19,12.76,0,0,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,6,6,1
"structures. BMC Bioinform. 22, 1–16 2021.","structures. BMC Bioinform. 22, 1–16 (2021).","30. Chen, D. et al. Algebraic graph-assisted bidirectional transformers for molecular property prediction. Nat. Commun. 12, 1–9","30.	 Chen, D. et al. Algebraic graph-assisted bidirectional transformers for molecular property prediction. Nat. Commun. 12, 1–9",-0.19,-12.76,0,0,1,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"30. Chen, D. et al. Algebraic graph-assisted bidirectional transformers for molecular property prediction. Nat. Commun. 12, 1–9","30.	 Chen, D. et al. Algebraic graph-assisted bidirectional transformers for molecular property prediction. Nat. Commun. 12, 1–9",2021,(2021).,-0.19,12.76,0,1,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,6,6,1
2021,(2021).,"31. Bishop, C. M., Svensén, M. & Williams, C. K. GTM: The generative topographic mapping. Neural Comput. 10, 215–234 1998.","31.	 Bishop, C. M., Svensén, M. & Williams, C. K. GTM: The generative topographic mapping. Neural Comput. 10, 215–234 (1998).",-0.19,-12.76,0,0,1,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"31. Bishop, C. M., Svensén, M. & Williams, C. K. GTM: The generative topographic mapping. Neural Comput. 10, 215–234 1998.","31.	 Bishop, C. M., Svensén, M. & Williams, C. K. GTM: The generative topographic mapping. Neural Comput. 10, 215–234 (1998).","32. Yoshimori, A. Prediction of molecular properties using molecular topographic map. Molecules 26, 4475 2021.","32.	 Yoshimori, A. Prediction of molecular properties using molecular topographic map. Molecules 26, 4475 (2021).",-0.19,0,1,1,1,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"32. Yoshimori, A. Prediction of molecular properties using molecular topographic map. Molecules 26, 4475 2021.","32.	 Yoshimori, A. Prediction of molecular properties using molecular topographic map. Molecules 26, 4475 (2021).","33. Ying, Z., Bourgeois, D., You, J., Zitnik, M. & Leskovec, J. Gnnexplainer: Generating explanations for graph neural networks.","33.	 Ying, Z., Bourgeois, D., You, J., Zitnik, M. & Leskovec, J. Gnnexplainer: Generating explanations for graph neural networks.",-0.19,0,1,1,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"33. Ying, Z., Bourgeois, D., You, J., Zitnik, M. & Leskovec, J. Gnnexplainer: Generating explanations for graph neural networks.","33.	 Ying, Z., Bourgeois, D., You, J., Zitnik, M. & Leskovec, J. Gnnexplainer: Generating explanations for graph neural networks.",Advances in Neural Information Processing Systems 32 2019.,Advances in Neural Information Processing Systems 32 (2019).,-0.21,12.76,0,0,0,7.5,7.5,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,6,6,1
Advances in Neural Information Processing Systems 32 2019.,Advances in Neural Information Processing Systems 32 (2019).,"34. Sundararajan, M., Taly, A. & Yan, Q. Axiomatic attribution for deep networks. In International Conference on Machine Learning,","34.	 Sundararajan, M., Taly, A. & Yan, Q. Axiomatic attribution for deep networks. In International Conference on Machine Learning,",-0.19,-12.76,0,0,1,7.5,7.5,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"34. Sundararajan, M., Taly, A. & Yan, Q. Axiomatic attribution for deep networks. In International Conference on Machine Learning,","34.	 Sundararajan, M., Taly, A. & Yan, Q. Axiomatic attribution for deep networks. In International Conference on Machine Learning,","3319–3328 PMLR, 2017.","3319–3328 (PMLR, 2017).",-0.19,12.76,0,1,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,6,6,1
"3319–3328 PMLR, 2017.","3319–3328 (PMLR, 2017).","35. Yang, W. et al. Genomics of drug sensitivity in cancer GDSC: A resource for therapeutic biomarker discovery in cancer cells.","35.	 Yang, W. et al. Genomics of drug sensitivity in cancer (GDSC): A resource for therapeutic biomarker discovery in cancer cells.",-0.19,-12.76,0,0,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"35. Yang, W. et al. Genomics of drug sensitivity in cancer GDSC: A resource for therapeutic biomarker discovery in cancer cells.","35.	 Yang, W. et al. Genomics of drug sensitivity in cancer (GDSC): A resource for therapeutic biomarker discovery in cancer cells.","Nucleic Acids Res. 41, D955–D961 2012.","Nucleic Acids Res. 41, D955–D961 (2012).",-0.21,12.76,0,0,0,7.5,7.5,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"Nucleic Acids Res. 41, D955–D961 2012.","Nucleic Acids Res. 41, D955–D961 (2012).",36. Cancer Cell Line Encyclopedia Consortium; Genomics of Drug Sensitivity in Cancer Consortium. Pharmacogenomic agreement,"36.	 Cancer Cell Line Encyclopedia Consortium; Genomics of Drug Sensitivity in Cancer Consortium. Pharmacogenomic agreement",-0.19,-12.76,0,0,0,7.5,7.5,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,6,6,1
36. Cancer Cell Line Encyclopedia Consortium; Genomics of Drug Sensitivity in Cancer Consortium. Pharmacogenomic agreement,"36.	 Cancer Cell Line Encyclopedia Consortium; Genomics of Drug Sensitivity in Cancer Consortium. Pharmacogenomic agreement","between two cancer cell line data sets. Nature 528, 84–87 2015.","between two cancer cell line data sets. Nature 528, 84–87 (2015).",-0.19,12.76,0,0,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,6,6,1
"between two cancer cell line data sets. Nature 528, 84–87 2015.","between two cancer cell line data sets. Nature 528, 84–87 (2015).","37. Wang, Y. et al. PubChem: A public information system for analyzing bioactivities of small molecules. Nucleic Acids Res. 37, W623–","37.	 Wang, Y. et al. PubChem: A public information system for analyzing bioactivities of small molecules. Nucleic Acids Res. 37, W623–",-0.19,-12.76,0,0,1,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"37. Wang, Y. et al. PubChem: A public information system for analyzing bioactivities of small molecules. Nucleic Acids Res. 37, W623–","37.	 Wang, Y. et al. PubChem: A public information system for analyzing bioactivities of small molecules. Nucleic Acids Res. 37, W623–",W633 2009.,W633 (2009).,-0.19,12.76,0,1,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,6,6,1
W633 2009.,W633 (2009).,38. RDKit: Open-source cheminformatics. http://www.rdkit.org. Online; Accessed 11-Apr.-2013.http://www.rdkit.org,"38.	 RDKit: Open-source cheminformatics. http://www.rdkit.org. [Online; Accessed 11-Apr.-2013].",-0.19,-12.76,0,0,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,6,6,1
38. RDKit: Open-source cheminformatics. http://www.rdkit.org. Online; Accessed 11-Apr.-2013.http://www.rdkit.org,"38.	 RDKit: Open-source cheminformatics. http://www.rdkit.org. [Online; Accessed 11-Apr.-2013].","39. Duan, Q. et al. L1000cds2: Lincs 1000 characteristic direction signatures search engine. NPJ Syst. Biol. Appl. 2, 1–12 2016.","39.	 Duan, Q. et al. L1000cds2: Lincs 1000 characteristic direction signatures search engine. NPJ Syst. Biol. Appl. 2, 1–12 (2016).",-0.19,0,1,0,1,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,6,6,1
"39. Duan, Q. et al. L1000cds2: Lincs 1000 characteristic direction signatures search engine. NPJ Syst. Biol. Appl. 2, 1–12 2016.","39.	 Duan, Q. et al. L1000cds2: Lincs 1000 characteristic direction signatures search engine. NPJ Syst. Biol. Appl. 2, 1–12 (2016).","40. Ramsundar, B. et al. Deep Learning for the Life Sciences O’Reilly Media, 2019. ?h?t?t ? p ? s?:?/ ? /?w ? w?w ? .?a?m?a ? z?o ? n?.?c ? o ? m?/?D?e?ehttps://www.amazon.com/Deep-Learning-Life-Sciences-Microscopy/dp/1492039837 ? p ? -?L?e?a?r?n?i?n?g?-?L?i?f?e?-?S?c?i?","40.	 Ramsundar, B. et al. Deep Learning for the Life Sciences (O’Reilly Media, 2019). ?h?t?t?p?s?:?/?/?w?w?w?.?a?m?a?z?o?n?.?c?o?m?/?D?e?e?p?-?L?e?a?r?n?i?n?g?-?L?i?f?e?-?S?c?i?",-0.19,0,1,1,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"40. Ramsundar, B. et al. Deep Learning for the Life Sciences O’Reilly Media, 2019. ?h?t?t ? p ? s?:?/ ? /?w ? w?w ? .?a?m?a ? z?o ? n?.?c ? o ? m?/?D?e?ehttps://www.amazon.com/Deep-Learning-Life-Sciences-Microscopy/dp/1492039837 ? p ? -?L?e?a?r?n?i?n?g?-?L?i?f?e?-?S?c?i?","40.	 Ramsundar, B. et al. Deep Learning for the Life Sciences (O’Reilly Media, 2019). ?h?t?t?p?s?:?/?/?w?w?w?.?a?m?a?z?o?n?.?c?o?m?/?D?e?e?p?-?L?e?a?r?n?i?n?g?-?L?i?f?e?-?S?c?i?",e?n?c?e?s?-?M?i?c?r?o?s?c?o?p?y?/?d?p?/?1?4?9?2?0?3?9?8?3?7.https://www.amazon.com/Deep-Learning-Life-Sciences-Microscopy/dp/1492039837 ?,e?n?c?e?s?-?M?i?c?r?o?s?c?o?p?y?/?d?p?/?1?4?9?2?0?3?9?8?3?7?.?,-0.19,12.76,0,0,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,6,6,1
e?n?c?e?s?-?M?i?c?r?o?s?c?o?p?y?/?d?p?/?1?4?9?2?0?3?9?8?3?7.https://www.amazon.com/Deep-Learning-Life-Sciences-Microscopy/dp/1492039837 ?,e?n?c?e?s?-?M?i?c?r?o?s?c?o?p?y?/?d?p?/?1?4?9?2?0?3?9?8?3?7?.?,"41. Vaswani, A. et al. Attention is all you need. Advances in Neural Information Processing Systems 30 2017.","41.	 Vaswani, A. et al. Attention is all you need. Advances in Neural Information Processing Systems 30 (2017).",-0.19,-12.76,0,0,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,6,6,1
"41. Vaswani, A. et al. Attention is all you need. Advances in Neural Information Processing Systems 30 2017.","41.	 Vaswani, A. et al. Attention is all you need. Advances in Neural Information Processing Systems 30 (2017).","42. Kipf, T. N. & Welling, M. Semi-supervised classification with graph convolutional networks. arXiv preprint arXiv:1609.02907http://arxiv.org/abs/1609.02907","42.	 Kipf, T. N. & Welling, M. Semi-supervised classification with graph convolutional networks. arXiv preprint arXiv:1609.02907",-0.19,0,1,0,1,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"42. Kipf, T. N. & Welling, M. Semi-supervised classification with graph convolutional networks. arXiv preprint arXiv:1609.02907http://arxiv.org/abs/1609.02907","42.	 Kipf, T. N. & Welling, M. Semi-supervised classification with graph convolutional networks. arXiv preprint arXiv:1609.02907",2016,-2016,-0.19,12.76,0,1,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,6,6,1
2016,-2016,"43. Velickovic, P. et al. Graph attention networks. arXiv preprint arXiv:1710.10903 2017.http://arxiv.org/abs/1710.10903","43.	 Velickovic, P. et al. Graph attention networks. arXiv preprint arXiv:1710.10903 (2017).",-0.19,-12.76,0,0,1,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"43. Velickovic, P. et al. Graph attention networks. arXiv preprint arXiv:1710.10903 2017.http://arxiv.org/abs/1710.10903","43.	 Velickovic, P. et al. Graph attention networks. arXiv preprint arXiv:1710.10903 (2017).","44. Schlichtkrull, M. et al. Modeling relational data with graph convolutional networks. In European Semantic Web Conference, 593–","44.	 Schlichtkrull, M. et al. Modeling relational data with graph convolutional networks. In European Semantic Web Conference, 593–",-0.19,0,1,1,1,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,6,6,1
"44. Schlichtkrull, M. et al. Modeling relational data with graph convolutional networks. In European Semantic Web Conference, 593–","44.	 Schlichtkrull, M. et al. Modeling relational data with graph convolutional networks. In European Semantic Web Conference, 593–","607 Springer, 2018.","607 (Springer, 2018).",-0.19,12.76,0,1,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,6,6,1
"607 Springer, 2018.","607 (Springer, 2018).","45. Busbridge, D., Sherburn, D., Cavallo, P. & Hammerla, N. Y. Relational graph attention networks. arXiv preprint arXiv:1904.05811http://arxiv.org/abs/1904.05811","45.	 Busbridge, D., Sherburn, D., Cavallo, P. & Hammerla, N. Y. Relational graph attention networks. arXiv preprint arXiv:1904.05811",-0.19,-12.76,0,0,1,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"45. Busbridge, D., Sherburn, D., Cavallo, P. & Hammerla, N. Y. Relational graph attention networks. arXiv preprint arXiv:1904.05811http://arxiv.org/abs/1904.05811","45.	 Busbridge, D., Sherburn, D., Cavallo, P. & Hammerla, N. Y. Relational graph attention networks. arXiv preprint arXiv:1904.05811",2019,-2019,-0.19,12.76,0,1,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,6,6,1
2019,-2019,"46. Brody, S., Alon, U. & Yahav, E. How attentive are graph attention networks? arXiv preprint arXiv:2105.14491 2021.http://arxiv.org/abs/2105.14491","46.	 Brody, S., Alon, U. & Yahav, E. How attentive are graph attention networks? arXiv preprint arXiv:2105.14491 (2021).",-0.19,-12.76,0,0,1,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"46. Brody, S., Alon, U. & Yahav, E. How attentive are graph attention networks? arXiv preprint arXiv:2105.14491 2021.http://arxiv.org/abs/2105.14491","46.	 Brody, S., Alon, U. & Yahav, E. How attentive are graph attention networks? arXiv preprint arXiv:2105.14491 (2021).","47. Kokhlikyan, N. et al. Captum: A unified and generic model interpretability library for pytorch. arXiv preprint arXiv:2009.07896http://arxiv.org/abs/2009.07896","47.	 Kokhlikyan, N. et al. Captum: A unified and generic model interpretability library for pytorch. arXiv preprint arXiv:2009.07896",-0.19,0,1,1,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,6,6,1
"47. Kokhlikyan, N. et al. Captum: A unified and generic model interpretability library for pytorch. arXiv preprint arXiv:2009.07896http://arxiv.org/abs/2009.07896","47.	 Kokhlikyan, N. et al. Captum: A unified and generic model interpretability library for pytorch. arXiv preprint arXiv:2009.07896",2020,(2020).,-0.19,12.76,0,0,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,6,6,1
2020,(2020).,"48. Shrikumar, A., Greenside, P., Shcherbina, A. & Kundaje, A. Not just a black box: Learning important features through propagating","48.	 Shrikumar, A., Greenside, P., Shcherbina, A. & Kundaje, A. Not just a black box: Learning important features through propagating",-0.19,-12.76,0,0,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"48. Shrikumar, A., Greenside, P., Shcherbina, A. & Kundaje, A. Not just a black box: Learning important features through propagating","48.	 Shrikumar, A., Greenside, P., Shcherbina, A. & Kundaje, A. Not just a black box: Learning important features through propagating",activation differences. arXiv preprint arXiv:1605.01713 2016.http://arxiv.org/abs/1605.01713,activation differences. arXiv preprint arXiv:1605.01713 (2016).,-0.19,12.76,0,0,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,6,6,1
activation differences. arXiv preprint arXiv:1605.01713 2016.http://arxiv.org/abs/1605.01713,activation differences. arXiv preprint arXiv:1605.01713 (2016).,"49. Bach, S. et al. On pixel-wise explanations for non-linear classifier decisions by layer-wise relevance propagation. PloS One 10,","49.	 Bach, S. et al. On pixel-wise explanations for non-linear classifier decisions by layer-wise relevance propagation. PloS One 10,",-0.19,-12.76,0,0,1,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,6,6,1
"49. Bach, S. et al. On pixel-wise explanations for non-linear classifier decisions by layer-wise relevance propagation. PloS One 10,","49.	 Bach, S. et al. On pixel-wise explanations for non-linear classifier decisions by layer-wise relevance propagation. PloS One 10,",e0130140 2015.,e0130140 (2015).,-0.19,12.76,0,1,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,6,6,1
e0130140 2015.,e0130140 (2015).,"50. Shrikumar, A., Greenside, P. & Kundaje, A. Learning important features through propagating activation differences. In International","50.	 Shrikumar, A., Greenside, P. & Kundaje, A. Learning important features through propagating activation differences. In International",-0.19,-12.76,0,0,1,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"50. Shrikumar, A., Greenside, P. & Kundaje, A. Learning important features through propagating activation differences. In International","50.	 Shrikumar, A., Greenside, P. & Kundaje, A. Learning important features through propagating activation differences. In International","Conference on Machine Learning, 3145–3153 PMLR, 2017.","Conference on Machine Learning, 3145–3153 (PMLR, 2017).",-0.21,12.76,0,1,0,7.5,7.5,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,6,6,1
"Conference on Machine Learning, 3145–3153 PMLR, 2017.","Conference on Machine Learning, 3145–3153 (PMLR, 2017).","51. Yuan, H., Yu, H., Wang, J., Li, K. & Ji, S. On explainability of graph neural networks via subgraph explorations. In International","51.	 Yuan, H., Yu, H., Wang, J., Li, K. & Ji, S. On explainability of graph neural networks via subgraph explorations. In International",-0.19,-12.76,0,0,1,7.5,7.5,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"51. Yuan, H., Yu, H., Wang, J., Li, K. & Ji, S. On explainability of graph neural networks via subgraph explorations. In International","51.	 Yuan, H., Yu, H., Wang, J., Li, K. & Ji, S. On explainability of graph neural networks via subgraph explorations. In International","Conference on Machine Learning, 12241–12252 PMLR, 2021.","Conference on Machine Learning, 12241–12252 (PMLR, 2021).",-0.21,12.76,0,1,0,7.5,7.5,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,6,6,1
"Conference on Machine Learning, 12241–12252 PMLR, 2021.","Conference on Machine Learning, 12241–12252 (PMLR, 2021).","52. Paszke, A. et al. Pytorch: An imperative style, high-performance deep learning library. In Wallach, H. et al. eds. Advances in","52.	 Paszke, A. et al. Pytorch: An imperative style, high-performance deep learning library. In Wallach, H. et al. (eds.) Advances in",-0.19,-12.76,0,0,0,7.5,7.5,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"52. Paszke, A. et al. Pytorch: An imperative style, high-performance deep learning library. In Wallach, H. et al. eds. Advances in","52.	 Paszke, A. et al. Pytorch: An imperative style, high-performance deep learning library. In Wallach, H. et al. (eds.) Advances in","Neural Information Processing Systems 32, 8024–8035 Curran Associates, Inc., 2019.","Neural Information Processing Systems 32, 8024–8035 (Curran Associates, Inc., 2019).",-0.21,12.76,0,0,0,7.5,7.5,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,6,6,1
"Neural Information Processing Systems 32, 8024–8035 Curran Associates, Inc., 2019.","Neural Information Processing Systems 32, 8024–8035 (Curran Associates, Inc., 2019).","53. Fey, M. & Lenssen, J. E. Fast graph representation learning with pytorch geometric. arXiv preprint arXiv:1903.02428 2019.http://arxiv.org/abs/1903.02428","53.	 Fey, M. & Lenssen, J. E. Fast graph representation learning with pytorch geometric. arXiv preprint arXiv:1903.02428 (2019).",-0.19,-12.76,0,0,1,7.5,7.5,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"53. Fey, M. & Lenssen, J. E. Fast graph representation learning with pytorch geometric. arXiv preprint arXiv:1903.02428 2019.http://arxiv.org/abs/1903.02428","53.	 Fey, M. & Lenssen, J. E. Fast graph representation learning with pytorch geometric. arXiv preprint arXiv:1903.02428 (2019).","54. Berman, H. M. et al. The protein data bank. Nucleic Acids Res. 28, 235–242 2000.","54.	 Berman, H. M. et al. The protein data bank. Nucleic Acids Res. 28, 235–242 (2000).",-0.19,0,1,1,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,6,6,1
"54. Berman, H. M. et al. The protein data bank. Nucleic Acids Res. 28, 235–242 2000.","54.	 Berman, H. M. et al. The protein data bank. Nucleic Acids Res. 28, 235–242 (2000).","55. Lu, J., Xia, S., Lu, J. & Zhang, Y. Dataset construction to explore chemical space with 3d geometry and deep learning. J. Chem. Inf.","55.	 Lu, J., Xia, S., Lu, J. & Zhang, Y. Dataset construction to explore chemical space with 3d geometry and deep learning. J. Chem. Inf.",-0.19,0,1,0,1,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"55. Lu, J., Xia, S., Lu, J. & Zhang, Y. Dataset construction to explore chemical space with 3d geometry and deep learning. J. Chem. Inf.","55.	 Lu, J., Xia, S., Lu, J. & Zhang, Y. Dataset construction to explore chemical space with 3d geometry and deep learning. J. Chem. Inf.","Model. 61, 1095–1104 2021.","Model. 61, 1095–1104 (2021).",-0.21,12.76,0,1,0,7.5,7.5,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"Model. 61, 1095–1104 2021.","Model. 61, 1095–1104 (2021).","56. Solca, F. et al. Target binding properties and cellular activity of afatinib BIBW 2992, an irreversible ErbB family blocker. J.","56.	 Solca, F. et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J. h",-0.19,-12.76,0,0,0,7.5,7.5,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"56. Solca, F. et al. Target binding properties and cellular activity of afatinib BIBW 2992, an irreversible ErbB family blocker. J.","56.	 Solca, F. et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J. h","Pharmacol. Exp. Ther. 343, 342–350 2012.","Pharmacol. Exp. Ther. 343, 342–350 (2012).",-0.21,12.76,0,0,0,7.5,7.5,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"Pharmacol. Exp. Ther. 343, 342–350 2012.","Pharmacol. Exp. Ther. 343, 342–350 (2012).","57. Canning, P. et al. Structural mechanisms determining inhibition of the collagen receptor ddr1 by selective and multi-targeted type","57.	 Canning, P. et al. Structural mechanisms determining inhibition of the collagen receptor ddr1 by selective and multi-targeted type",-0.19,-12.76,0,0,0,7.5,7.5,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"57. Canning, P. et al. Structural mechanisms determining inhibition of the collagen receptor ddr1 by selective and multi-targeted type","57.	 Canning, P. et al. Structural mechanisms determining inhibition of the collagen receptor ddr1 by selective and multi-targeted type","ii kinase inhibitors. J. Mol. Biol. 426, 2457–2470 2014.","ii kinase inhibitors. J. Mol. Biol. 426, 2457–2470 (2014).",-0.19,12.76,0,0,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,6,6,1
"ii kinase inhibitors. J. Mol. Biol. 426, 2457–2470 2014.","ii kinase inhibitors. J. Mol. Biol. 426, 2457–2470 (2014).","58. Abouantoun, T. J., Castellino, R. C. & MacDonald, T. J. Sunitinib induces PTEN expression and inhibits PDGFR signaling and","58.	 Abouantoun, T. J., Castellino, R. C. & MacDonald, T. J. Sunitinib induces PTEN expression and inhibits PDGFR signaling and",-0.19,-12.76,0,0,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"58. Abouantoun, T. J., Castellino, R. C. & MacDonald, T. J. Sunitinib induces PTEN expression and inhibits PDGFR signaling and","58.	 Abouantoun, T. J., Castellino, R. C. & MacDonald, T. J. Sunitinib induces PTEN expression and inhibits PDGFR signaling and","migration of medulloblastoma cells. J. Neuro-oncol. 101, 215–226 2011.","migration of medulloblastoma cells. J. Neuro-oncol. 101, 215–226 (2011).",-0.19,12.76,0,0,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,6,6,1
"migration of medulloblastoma cells. J. Neuro-oncol. 101, 215–226 2011.","migration of medulloblastoma cells. J. Neuro-oncol. 101, 215–226 (2011).","59. Freshour, S. L. et al. Integration of the drug–gene interaction database DGIdb 4.0 with open crowdsource efforts. Nucleic Acids","59.	 Freshour, S. L. et al. Integration of the drug–gene interaction database (DGIdb 4.0) with open crowdsource efforts. Nucleic Acids",-0.19,-12.76,0,0,1,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"59. Freshour, S. L. et al. Integration of the drug–gene interaction database DGIdb 4.0 with open crowdsource efforts. Nucleic Acids","59.	 Freshour, S. L. et al. Integration of the drug–gene interaction database (DGIdb 4.0) with open crowdsource efforts. Nucleic Acids","Res. 49, D1144–D1151 2021.","Res. 49, D1144–D1151 (2021).",-0.21,12.76,0,1,0,7.5,7.5,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,6,6,1
"Res. 49, D1144–D1151 2021.","Res. 49, D1144–D1151 (2021).","60. Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression","60.	 Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression i",-0.19,-12.76,0,0,0,7.5,7.5,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"60. Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression","60.	 Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression i","profiles. Proc. Natl. Acad. Sci. 102, 15545–15550 2005.","profiles. Proc. Natl. Acad. Sci. 102, 15545–15550 (2005).",-0.19,12.76,0,0,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,6,6,1
"profiles. Proc. Natl. Acad. Sci. 102, 15545–15550 2005.","profiles. Proc. Natl. Acad. Sci. 102, 15545–15550 (2005).","61. Fang, Z., Liu, X. & Peltz, G. GSEApy: A comprehensive package for performing gene set enrichment analysis in python.","61.	 Fang, Z., Liu, X. & Peltz, G. GSEApy: A comprehensive package for performing gene set enrichment analysis in python.",-0.19,-12.76,0,0,0,7.5,7.5,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"61. Fang, Z., Liu, X. & Peltz, G. GSEApy: A comprehensive package for performing gene set enrichment analysis in python.","61.	 Fang, Z., Liu, X. & Peltz, G. GSEApy: A comprehensive package for performing gene set enrichment analysis in python.","Bioinformatics 39, btac757 2023.","Bioinformatics 39, btac757 (2023).",-0.21,12.76,0,0,0,7.5,7.5,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,6,6,1
"Bioinformatics 39, btac757 2023.","Bioinformatics 39, btac757 (2023).",Acknowledgements,Acknowledgements,1,-12.76,0,0,0,7.5,11,3.5,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,6,6,0
Acknowledgements,Acknowledgements,"This research was supported by AcRF Tier-1 grant RG14/23 of Ministry of Education, Singapore.","This research was supported by AcRF Tier-1 grant RG14/23 of Ministry of Education, Singapore.",-0.17,0,1,0,1,11,9,-2,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,6,6,0
"This research was supported by AcRF Tier-1 grant RG14/23 of Ministry of Education, Singapore.","This research was supported by AcRF Tier-1 grant RG14/23 of Ministry of Education, Singapore.",Author contributions,Author contributions,0.94,0,1,1,0,9,11,2,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,6,6,0
Author contributions,Author contributions,"C.W., A.K.G., and J.C.R. conceived the experiments, C.W. and A.K.G. conducted the experiments, C.W.,","C.W., A.K.G., and J.C.R. conceived the experiment(s), C.W. and A.K.G. conducted the experiment(s), C.W.,",-0.17,0,1,0,0,11,9,-2,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,6,6,0
"C.W., A.K.G., and J.C.R. conceived the experiments, C.W. and A.K.G. conducted the experiments, C.W.,","C.W., A.K.G., and J.C.R. conceived the experiment(s), C.W. and A.K.G. conducted the experiment(s), C.W.,","J.C.R., and A.K.G. analysed the results. C.W. and J.C.R. wrote and reviewed the manuscript.","J.C.R., and A.K.G. analysed the results. C.W. and J.C.R. wrote and reviewed the manuscript.",-0.24,0,1,0,1,9,9,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,6,6,1
"J.C.R., and A.K.G. analysed the results. C.W. and J.C.R. wrote and reviewed the manuscript.","J.C.R., and A.K.G. analysed the results. C.W. and J.C.R. wrote and reviewed the manuscript.",Declarations,Declarations,0.94,0,1,1,0,9,11,2,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,6,6,0
Declarations,Declarations,Competing interests,Competing interests,1.01,0,1,0,0,11,11,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,6,6,0
Competing interests,Competing interests,The authors declare no competing interests.,The authors declare no competing interests.,-0.17,0,1,0,0,11,9,-2,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,6,6,0
The authors declare no competing interests.,The authors declare no competing interests.,Scientific Reports 2025 15:179 https://doi.org/10.1038/s41598-024-83090-3 13,| https://doi.org/10.1038/s41598-024-83090-3,1.67,69.94,0,0,1,9,8,-1,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,6,6,0
Additional information,Additional information,Correspondence and requests for materials should be addressed to J.C.R.,Correspondence and requests for materials should be addressed to J.C.R.,-0.52,0,1,0,0,11,9,-2,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,7,7,0
Correspondence and requests for materials should be addressed to J.C.R.,Correspondence and requests for materials should be addressed to J.C.R.,Reprints and permissions information is available at www.nature.com/reprints.,Reprints and permissions information is available at www.nature.com/reprints.,0.73,0,1,0,0,9,9,0,1,1,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,7,7,0
Reprints and permissions information is available at www.nature.com/reprints.,Reprints and permissions information is available at www.nature.com/reprints.,Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and,Publisher’s note  Springer Nature remains neutral with regard to jurisdictional claims in published maps and,0.73,0,1,0,0,9,9,0,1,1,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,7,7,0
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and,Publisher’s note  Springer Nature remains neutral with regard to jurisdictional claims in published maps and,institutional affiliations.,institutional affiliations.,-0.6,0,1,0,0,9,9,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,7,7,1
institutional affiliations.,institutional affiliations.,Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives,Open Access   This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives,1,0,1,0,0,9,9,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,7,7,0
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives,Open Access   This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives,"4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in","4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in",-0.6,0,1,0,0,9,9,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,7,7,1
"4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in","4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in","any medium or format, as long as you give appropriate credit to the original authors and the source, provide","any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide",-0.6,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,7,7,1
"any medium or format, as long as you give appropriate credit to the original authors and the source, provide","any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide","a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have","a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have",-0.6,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,7,7,1
"a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have","a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have",permission under this licence to share adapted material derived from this article or parts of it. The images or,permission under this licence to share adapted material derived from this article or parts of it. The images or,-0.6,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,7,7,1
permission under this licence to share adapted material derived from this article or parts of it. The images or,permission under this licence to share adapted material derived from this article or parts of it. The images or,"other third party material in this article are included in the article’s Creative Commons licence, unless indicated","other third party material in this article are included in the article’s Creative Commons licence, unless indicated",-0.6,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,7,7,1
"other third party material in this article are included in the article’s Creative Commons licence, unless indicated","other third party material in this article are included in the article’s Creative Commons licence, unless indicated",otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence,otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence,-0.6,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,7,7,1
otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence,otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence,"and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to","and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to",-0.6,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,7,7,1
"and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to","and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to","obtain permission directly from the copyright holder. To view a copy of this licence, visit ?h?t?t?p?:?/?/?c?r?e?a?t?i?v?e?c?o?m?m?o?http://creativecommons.org/licenses/by-nc-nd/4.0/","obtain permission directly from the copyright holder. To view a copy of this licence, visit ?h?t?t?p?:?/?/?c?r?e?a?t?i?v?e?c?o?m?m?o?",-0.6,0,1,0,1,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,7,7,1
"obtain permission directly from the copyright holder. To view a copy of this licence, visit ?h?t?t?p?:?/?/?c?r?e?a?t?i?v?e?c?o?m?m?o?http://creativecommons.org/licenses/by-nc-nd/4.0/","obtain permission directly from the copyright holder. To view a copy of this licence, visit ?h?t?t?p?:?/?/?c?r?e?a?t?i?v?e?c?o?m?m?o?",n?s?.?o?r?g?/?l?i?c?e?n?s?e?s?/?b?y?-?n?c?-?n?d?/?4?.?0?/.http://creativecommons.org/licenses/by-nc-nd/4.0/ ?,n?s?.?o?r?g?/?l?i?c?e?n?s?e?s?/?b?y?-?n?c?-?n?d?/?4?.?0?/?.?,-0.6,0,1,1,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,7,7,1
n?s?.?o?r?g?/?l?i?c?e?n?s?e?s?/?b?y?-?n?c?-?n?d?/?4?.?0?/.http://creativecommons.org/licenses/by-nc-nd/4.0/ ?,n?s?.?o?r?g?/?l?i?c?e?n?s?e?s?/?b?y?-?n?c?-?n?d?/?4?.?0?/?.?,© The Authors 2024,© The Author(s) 2024,2.44,0,1,0,0,9,9,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,7,7,0
© The Authors 2024,© The Author(s) 2024,Scientific Reports 2025 15:179 https://doi.org/10.1038/s41598-024-83090-3 14,| https://doi.org/10.1038/s41598-024-83090-3,146.02,69.94,0,0,1,9,8,-1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,7,7,0
